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ABSTRACT 
Inflammatory bowel disease (IBD) is one of the most common immune-mediated 
diseases in the United States costing the average patient tens of thousands of dollars 
annually, and greatly diminishing quality-of-life.  While there is no universal cure for 
IBD, recently developed treatments targeting the immunological basis of disease have 
proven successful in managing clinical symptoms.  However, these pharmaceutical 
therapies such as infliximab (Remicade®) carry several side effects and are not 
efficacious in all patients.  Thus, more selective treatments are needed.  One necessary 
step in the development of such agents is a more precise understanding of which cells in 
the gastrointestinal tract are primary contributors to the pathogenesis of IBD.   
We demonstrate that a rare subset of dendritic cells expressing CD8α is present in 
significantly different numbers in mouse strains considered susceptible or resistant to a 
microbially induced model of IBD.  Additionally, we show that cells derived from the 
target organ of susceptible mice prior to and shortly after induction of the disease process 
are prone to production of greater levels of certain inflammatory mediators including IL-
12/23p40, IP-10, RANTES, and TNF-α.  Lastly, we describe the generation of a mouse 
strain susceptible to the disease model but selectively lacking the subset of dendritic cells 
expressing CD8α, to be used in future studies. 
One of the most serious sequela to IBD is colitis-associated colorectal cancer (CAC).  
Diagnosis of colorectal cancer in general is reliant on tests that suffer from either poor 
sensitivity or specificity (such as fecal occult blood tests), or invasiveness (such as 
colonoscopy).  Newer genetic tests have been developed for the identification of 
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hereditary risk factors, however CAC follows a molecular pathway distinct from that of 
familial forms of colorectal cancer.  Thus, the development of noninvasive screening 
assays for CAC with high sensitivity and specificity would increase compliance with 
screening recommendations and enhance detection and survival of patients with CAC.   
We report here the development of a novel screening technique capable of detecting the 
earliest stages of CAC in a microbially induced mouse model.  Using fecal gene 
expression-based biomarkers, rRNA derived from colonocytes sloughed in the feces, we 
were able to accurately predict which mice would develop CAC several weeks later, as 
well as predict the severity of disease.  While the optimal markers of disease identified in 
the present studies, IL-1β and MIP-1α, are likely specific to this model of CAC, the 
proof-of-concept portends a powerful new method of diagnostics for CAC in humans. 
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CHAPTER 1 
INTRODUCTION 
The human gastrointestinal tract (GIT) is an organ faced with unique challenges and, in 
most individuals, endowed with the capacity to handle those challenges. The GIT is 
essentially a long tube in direct contact with the external environment at either end, i.e. 
the mouth and anus, constituting the largest surface area in the body exposed to bacteria
1
.  
A single layer of epithelial cells connected to each other via tight junctions is the only 
thing separating the myriad bacteria within the lumen of the GIT from underlying cells 
and tissues.  Among those cells beneath the intestinal epithelium are various types of 
dendritic cells capable of extending pseudopodia between epithelial cells in a tight-
junction-mediated manner and sampling the intestinal microbiota.  Additionally, 
specialized M-cells overlying lymphoid follicles in the intestinal mucosa transcytose 
bacteria to underlying antigen-presenting cells. These cells, each possessing surface 
molecules capable of detecting pathogenic and non-pathogenic microbes, must be able to 
determine the correct response to the microbes within the GIT and direct the immune 
response accordingly via production of cell-surface co-stimulatory molecules and 
secreted molecules such as cytokines and chemokines.  Within the lumen of the GIT 
resides a dynamic ecological community with a richness and diversity comparable to any 
environmental ecological niches known to man. This complex community of microbes 
consisting of members of all three biological domains, Bacteria, Archaea, and Eukarya, is 
dominated by eubacteria with densities of greater than 1×10
11
/gram of feces in the colon. 
In an average adult, prokaryotes in the GIT outnumber somatic cells by an order of 
magnitude.  The composition of this dense and diverse population is largely stable in 
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healthy adults but, as in any population of this size, it is dynamic and may experience 
fluctuations in the relative frequency of specific microbial species from time to 
time.  This microbiota is recognized by the innate immune system which, in turn, directs 
the host response.  The studies described in the following dissertation investigate the 
contribution of CD8α+ dendritic cells in the pathogenesis of a model of inflammatory 
bowel disease (Chapter 2), the noninvasive detection of colitis-associated colorectal 
cancer in a microbially induced model (Chapter 3), and the impact of acute infection with 
Murine Norovirus on two chemically induced models if inflammatory bowel disease 
(Chapter 4).  It is the goal of the author that the findings detailed herein will advance the 
field of gastroenterology and immunology in such a fashion as to lead us one step closer 
to more effective therapeutic and diagnostic techniques in humans. 
SIGNIFICANCE OF INFLAMMATORY BOWEL DISEASE 
Inflammatory bowel disease (IBD) is one of the most common chronic immune-mediated 
diseases in the Western world affecting approximately 1.4 million people in the U.S. and 
close to 3 million people in Europe
2
.  In addition, the incidence and prevalence of IBD is 
increasing worldwide, particularly in countries with a Western lifestyle.  Traditionally, a 
diagnosis of IBD is classified as either ulcerative colitis (UC) or Crohn’s disease (CD) 
although there is considerable variation in clinical disease presentation and histological 
appearance of diseased tissues within either form of IBD.  Additionally, approximately 
10% of IBD cases not meeting the criteria for a diagnosis of UC or CD are deemed 
indeterminate colitis.  Clinical manifestations of IBD are typically waxing and waning 
and most commonly include diarrhea or loose stool, constipation, painful abdominal 
cramping, hematochezia or melena depending on the anatomical location of ulcerated 
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areas, and the sensation of incomplete evacuation.  General symptoms associated with 
IBD include fever, loss of appetite, fatigue, weight loss, and a loss of normal menstrual 
cycles in females.   
While there are overlapping causative factors in UC and CD, there are distinct phenotypic 
differences.  As the name implies, UC is restricted to the colon (and occasionally the 
rectum) while sparing the perianal region.  Alternatively, CD can affect any region of the 
gastrointestinal tract from the mouth to the anus and perianal involvement is common.  
Affected areas are continuous in UC while so-called “skip areas” of unaffected mucosa 
are common in CD.  The depth of inflammation also varies between the two forms of 
IBD with substantial consequence; while histological examination of UC reveals 
inflammation extending only into the lamina propria, the inflammatory infiltrates in CD 
are frequently transmural, leading to fistulae necessitating surgical repair.  Similarly, 
while strictures and granulomata are common in CD, these are seen only occasionally in 
UC patients.   
The inflammation and subsequent damage to the intestinal mucosa may also lead to 
significant sequelae, some of which are as, if not more, problematic than IBD itself.  One 
of the most common consequences of IBD is nutritional deficiency, with protein, iron, 
and vitamin D being some of the most commonly deficient components
3-5
.  Other factors 
shown to be lacking in IBD patients include magnesium, and vitamins B9 and B12.  Not 
surprisingly, these are primarily a problem of CD patients with small intestinal 
involvement; however malnutrition can affect patients with any form of IBD even when 
disease is quiescent
3
.  There are several factors leading to malnutrition including 
malabsorption, lack of appetite, increased losses in feces, and the overall shift in 
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metabolic function due to chronic inflammation.  Of note, malnutrition often leads to its 
own set of health issues including poor wound healing, anemia, osteoporosis, and, in case 
of pediatric IBD, stunted growth.  One of the most devastating sequelae to IBD is 
development of colitis-associated colorectal cancer (CAC), thought to be induced by the 
abundant reactive oxygen species produced by activated cells of the immune system, as 
well as the increased rate of epithelial cell turn-over in the gut.  Along with hereditary 
predispositions such as Familial Adenomatous Polyposis (FAP) and Hereditary Non-
Polyposis Colorectal Cancer (HNPCC), chronic inflammation is one of three primary risk 
factors for colorectal cancer.  CAC is however distinct from sporadic and familial forms 
of colorectal cancer with regard to its molecular pathogenesis and phenotypic 
progression.  These topics will be reviewed further beginning on page 19. 
IBD can affect individuals of almost any age and, while the incidence of pediatric IBD is 
increasing, disease is most often diagnosed during late adolescence or early adulthood.  A 
diagnosis of CD carries a relatively modest increase in mortality while UC appear to 
affect mortality to a lesser degree
6, 7
.  Additionally, while partial or total colectomy may 
be curative in rare cases of UC, the majority of IBD cases must be managed for the life of 
the patient making IBD as costly to the individual and the health care industry as other 
chronic diseases such as congestive heart failure and cancer
8
.  Costs associated with IBD 
include medications, hospitalization, and surgery, as well as lost wages due to disability 
which account for almost 50% of total costs
9-11
.  The recent advent of effective but 
expensive biologic therapies such as anti-tumor necrosis factor (TNF)-α have shifted the 
profile of these costs via a decrease in costs related to hospitalization and surgery and a 
concomitant increase in costs related to pharmaceuticals
12
.  Health care costs tend to be 
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greatest during the initial few years after the diagnosis of IBD is made followed by a 
plateau at slightly lower costs, with lifetime mean direct costs of $4232 and $3552 
annually for Canadian patients with CD and UC respectively
13
.  A recent U.S. study 
determined that patients with mild IBD incurred average annual health care costs of 
$10,687 whereas patients with moderate to severe IBD had average annual costs of 
$37,925
8
.  These figures do not account for indirect costs which are generally considered 
to be equal to, or greater than, direct costs, due to the facts that IBD generally occurs in 
the most economically productive years of life, and that it is typically a nonfatal disease 
requiring life-long management
14, 15
.  Additionally, as the prevalence of IBD in the U.S 
increases, so do health care costs; inflation-adjusted total charges attributable to CD 
hospitalizations increased an average of 10.5% annually between 1998 and 2004
16
.   
Along with the physical and financial burden placed on individuals diagnosed with IBD, 
there is a tremendous psychological burden.  Individuals living with chronic illnesses 
such as IBD report feelings of diminished self-worth, shame, and embarrassment.  This 
sense of stigma is often perceived to exist in health care settings and, whether real or not, 
can lead to delayed health care and decreased quality of life
17
.  IBD can also lead to 
depression and anger due to the impact of IBD on a patient’s lifestyle such as dietary 
changes, cessation of smoking, or loss of productivity.  One recent study of IBD patients 
demonstrated a significant correlation between the level of depression and the number of 
relapses experienced
18
.  Thus, the negative effect of IBD on mood and self-worth can in 
turn exacerbate disease leading to a vicious cycle.   
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PATHOGENESIS OF INFLAMMATORY BOWEL DISEASE 
The pathogenesis of IBD is complex and multifactorial.  Susceptibility is determined by a 
combination of genetics and multiple environmental factors including, but not limited to, 
geography, diet, smoking, and stress.  Researchers have long known that genetics played 
a large role in disease susceptibility based on studies of familial cohorts
19, 20
 and twins
21-
24
.  Overall, estimates of the contribution of genetics to disease susceptibility are 
approximately 50%
25, 26
.  Genome-wide association studies (GWAS) have identified 
several genes linked to IBD susceptibility and resistance
27, 28
, many of which are 
associated with the innate immune system and intuitively involved in the pathogenesis of 
IBD.  Using standard linkage analysis rather than a GWAS, the first genetic 
polymorphisms associated with IBD occurred in the gene encoding Nucleotide 
oligomerisation domain-containing protein 2 or Nod2 (also known as Caspase 
Recruitment Domain 15 or CARD15)
29-31
.  Expressed primarily in leukocytes and Paneth 
cells
32
, Nod2 is an intracellular protein which recognizes muramyl dipeptide (MDP)
33
, a 
peptidoglycan component of both Gram positive and Gram negative bacteria.  The C-
terminal of Nod2 contains a leucine-rich repeat (LRR) domain which physically binds 
MDP, while the N-terminal portion contains two caspase-recruitment (CARD) domains 
capable of initiating apoptosis and activating inflammatory NF-κB pathways34.  Three 
principal mutations have been identified in the Nod2 gene conferring increased 
susceptibility to IBD (Arg702Trp, Gly908Arg, and Leu1007fs)
35
 and all three occur in 
the region encoding the LRR domain, implying that these mutations affect the ability of 
Nod2 to bind MDP normally.  Highlighting the contribution of other genetic and 
environmental factors however, these same mutations do not appear to predispose some 
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Asian populations to IBD
36, 37
.  Additionally, while homozygous and compound 
heterozygous Nod2 mutations are estimated to increase the risk of IBD from 10 to 40 
times the general population, a substantial proportion of healthy people also possess those 
genotypes
38
.  Considering its location in the cytosol, the physiological function of Nod2 
is presumably to recognize intracellular bacteria.  While acute signaling through Nod2 
initiates NF-κB and MAP kinase-driven inflammatory responses39, chronic stimulation of 
Nod2 leads to a tolerogenic response
40
, suggesting that the chronicity of binding also 
affects the ensuing immune response.  Thus, individuals possessing mutated forms of 
Nod2 may be unable to mount proper immune responses against invasive microbial 
species, or to induce tolerance to commensal microbes collected from the intestinal 
lumen via CX3CR1-mediated sampling by dendritic cells.  Nod2 has also been shown to 
work synergistically with other pathogen-associated molecular pattern receptors such as 
Toll-like receptor 2 (TLR2), TLR3, and TLR4
41, 42
.  Thus, like TLRs, Nod2 can serve as 
an inducer of inflammatory or tolerogenic responses.  As an example of the latter, the 
beneficial effects of certain lactobacilli have been shown to be mediated through Nod2
43
.  
Perhaps not surprisingly, Nod2 is recognized to play a critical role in modulating the 
intestinal microbiota
44
 via modulating the response of T cells, the production of 
antimicrobial defensins
45, 46
, and the permeability of the intestinal epithelium
47
.   
GWAS have identified other pathways associated with IBD susceptibility including 
autophagy and several inflammatory cytokines and cytokine receptors.  Autophagy, once 
considered strictly a process by which intracellular organelles can be degraded and their 
components recycled, is now recognized to also serve as a means of eradicating 
intracellular microbes.  In the process of autophagy, cytoplasmic material is engulfed in 
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membrane-enclosed autophagosomes which then fuse with endosomes and lysosomes to 
form autophagosomes in which degradation occurs.  The first component of this process 
to be associated with IBD was Autophagy-related protein 16-L1 (ATG16L1)
48-50
, a 
subunit of the large protein complex necessary for autophagy.  Subsequently, variants of 
the protein Immunity-related GTPase M (IRGM), essential for the initiation phase of 
autophagy and the clearance of certain intracellular microbes
51, 52
, have been linked to 
IBD susceptibility
53
.  Surprisingly, two recent reports suggest that Nod2 may regulate 
autophagy and that Nod2 and ATG16L1 may even physically interact
54, 55
.  The nature of 
this interaction is not completely understood and is an active area of research.  Cytokines 
implicated in the pathogenesis of IBD include IL-23, IL-10, IL-1β, IL-12, IL-27, IL-2, 
and TNF-α, among others.  Additionally, multiple chemokines affecting leukocyte 
recruitment to the gut, mucin proteins contributing to epithelial barrier function, and 
transcription factors involved in myriad pathways have been associated with the risk of 
developing IBD, all of which speak to the remarkable complexity of the pathogenesis of 
IBD.   
Despite the number of genetic factors now linked to disease susceptibility, the exact 
nature of IBD pathophysiology is still largely unknown.  Attempts to identify a 
pathogenic microbial etiology have been, as a whole, unfruitful.  The histological and 
endoscopic appearance of CD bears a resemblance to infection with Mycoplasma 
tuberculosis and Yersinia spp. while acute UC has strong similarities to Shigella and 
Campylobacter infections
56
.  That being said, none of these pathogens have been 
consistently recovered from affected patients.  One bacteria receiving considerable 
attention as a possible causative agent is Mycobacterium avium subspecies 
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paratuberculosis (MAP), the cause of Johne’s disease, a chronic granulomatous enteritis 
of cattle.  MAP has been recovered from several CD patients and increased antibody 
titers against certain mycobacterial antigens have been noted.  However, 
immunohistochemical and clinical studies have failed to support the notion that MAP is 
causative in IBD
57, 58
.  Additionally, PCR-based attempts to support the role of MAP in 
IBD have shown that while sequences specific for mycobacteria can be isolated from 
intestinal tissue, they are not specific for CD
57, 58
.  Others have proposed that in utero or 
childhood exposure to one of several viral pathogens may lead to CD years later.  Viruses 
hypothesized at one point to play a role include the paramyxoviruses responsible for the 
measles and mumps
59, 60
, and Epstein-Barr virus
61
 and cytomegalovirus
62
, both human 
herpesviruses.  As with the bacterial agents mentioned above, these hypotheses have been 
discredited as causative agents
63-65
 and any weak positive associations between childhood 
infection with, or vaccination against, these agents are now considered, at best, 
environmental factors contributing to IBD risk.  Thus barring the identification of an as 
yet uncharacterized intestinal microbe more strongly associated with IBD, there is no 
convincing evidence that IBD is caused by a single bacteria or virus.  Additionally, even 
in the unlikely event that such a microbe is identified, the contribution of genetic risk 
factors is irrefutable. 
There has also been considerable investigation into IBD being an autoimmune disease 
targeting a host protein, particularly in UC
66-69
.  Anti-neutrophil antibodies have been 
studied extensively, with conflicting results.  While elevated anti-neutrophil titers have 
been detected in some IBD patients
70, 71
, their presence is not diagnostic of IBD and titers 
do not correlate with disease activity in UC
72
.  One theory, termed molecular mimicry, 
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holds that specific bacterial epitopes share immunological determinants with host 
proteins.  One example posits that the mycobacterial heat shock protein heat shock 
protein 65 (HSP65) shares sufficient homology with human HSP60 to induce an 
autoimmune response.  These findings have achieved little support.  Thus, the 
endogenous antigens, be they microbial or host-associated, remain elusive. 
In contrast to hypotheses revolving around immune responses to an unidentified 
pathogenic organism or host epitope, the commonly accepted theory is that IBD results 
from an aberrant immune response against some component of the commensal 
microbiota.  This notion is supported in animal models of IBD, almost none of which 
develop intestinal inflammation when performed in germ-free animals.  In the human 
condition, there are several pieces of evidence suggesting that autochthonous bacteria are 
the target of the inflammatory immune responses in IBD.  Clinically, treatment with 
antibiotics or surgical diversion of the fecal stream has shown to have positive effects in 
many CD patients.  Histological analysis has revealed that the mucosa is relatively free of 
adherent bacteria in the normal GIT
73
.  In IBD patients however, there is an increased 
presence of bacterial antigens within the mucosa, including antigens derived from E. coli, 
Streptococcus spp., and Listeria spp
73-76
.  However, while immunoreactivity is most 
commonly localized to fissures, granulomatous tissue, and abscesses, it is unclear 
whether these agents are causally related or opportunistic.  Similarly, studies have 
demonstrated increased levels of circulating antibodies against intestinal bacteria
77, 78
, the 
significance of which is yet unknown.  A prevailing theory, supported by studies using 
animal models holds that certain bacterial species function as provocateurs of immune 
responses against commensal bacteria by compromising the mucosal barrier function.  
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Using a mouse model driven by experimental inoculation with Helicobacter bilis or H. 
hepaticus, Wannemuehler et al. showed that several weeks after inoculation, antibodies 
against commensal bacteria consistently appeared in mice, despite any overt defects in 
the mucosal lining, e.g. ulceration
79, 80
.  Supporting this theory in humans, Rocha et al. 
demonstrated the ability of E. coli to enhance the permeability of cultured epithelial cell 
monolayers
81
.  It is unknown how the supposed provocateurs induce this alteration in 
permeability and there is considerable work to be done in this field.  Collectively, these 
data support the hypothesis that IBD results from a dysregulated immune response to 
commensal bacteria. 
ANIMAL MODELS OF INFLAMMATORY BOWEL DISEASE 
While no animal model of IBD recapitulates every aspect of the human condition, such 
reductionist approaches provide important information on the development of disease and 
factors predisposing individuals to disease.  Owing to our ability to manipulate the mouse 
genome, mice are the most widely used model species in most fields of biomedical 
research and studies of IBD are no exception.  Inflammation is induced in these models 
via oral or rectal administration of chemical compounds, genetic alteration, microbial 
inoculation, or adoptive transfer of cells.   
The two most commonly used chemically induced mouse models of IBD are DSS- and 
TNBS-induced colitis.  In DSS colitis, the causative agent dextran sulfate sodium, a 
highly sulfated polysaccharide of very high molecular weight (typically 5 to 40 kDa), is 
administered in the drinking water.  First developed by Ohkusa et al. in hamsters
82
, the 
technique was soon translated to mice
83
 and has become a classic method of inducing 
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colitis and potentially colorectal cancer when administered chronically in susceptible 
strains of mice.  Disease severity is dependent on multiple factors including mouse 
strain
84
, mouse sex, molecular weight of DSS
85
, duration of exposure to DSS
86
, and even 
the stress level of mice
87
.  In the GIT, DSS penetrates the mucosal epithelium and can be 
visualized within antigen-presenting cells in the colon and mesenteric lymph nodes 
within 24 hours of the first dose
88
.  Acute colitis can be induced in susceptible mouse 
strains by continuous administration of 2-5% DSS for periods as short as 4 days.  Chronic 
colitis is induced via prolonged administration of lower concentrations or by cyclical 
dosing.  Histologically, DSS induces an initial loss of crypts followed by epithelial 
ulceration and abscessation
89
.  Thus DSS colitis is often described histologically as 
suppurative colitis with ulceration.  Despite the overt toxicity of DSS to colonic epithelial 
cells, the intestinal microbiota is essential for the development of inflammation
90
, 
indicating the necessity of the microbiota for disease. 
2,4,6-trinitrobenzene sulfonic acid (TNBS) is used to induced colitis via rectal 
administration in approximately 50% ethanol.  As in DSS colitis, there are differences in 
strain susceptibility.  In susceptible strains, greater than 90% of TNBS-treated mice will 
develop acute colitis followed by weight loss and diarrhea within days to weeks.  The age 
of mice is a critical factor as mice less than 4 weeks of age will experience excessive 
mortality whereas mice greater than 8 weeks of age will develop much milder, if any, 
disease
91
.  Additionally, proper storage and dosage of TNBS are important 
considerations.  It is thought that the trinitrophenyl moiety of TNBS haptenates host 
proteins, and also evokes a cross-reactive immune response, cellular elements of which 
recognize portions of the microbiota.  This was supported by experiments by Neurath et 
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al. demonstrating that disease can be transferred with T cells extracted from the lamina 
propria of TNBS-treated mice to naïve mice in the absence of TNBS
92
.  Cytokine profiles 
from TNBS-treated mice indicate that inflammation is driven by TH1-skewed CD4
+
 T 
cells
93
, similar to IBD in humans
94, 95
.  Histologically, TNBS administration leads to 
dense transmural mononuclear cell infiltration and a loss of normal crypt architecture. 
A detailed description of genetically manipulated murine models of IBD is beyond the 
scope of this section.  It suffices to say that these models, including but not limited to IL-
2
-/-96, Gαi2-/-97, TCRα-/-98, TCRβ-/-99, Mdr1-/-100, MUC2-/-101, ITF-/-102, TNFΔARE103, and 
Stat4-transgenic
104
 mice all possess strengths and weaknesses.  Of note however is the 
well-characterized IL-10
-/-
 mouse, originally developed by Kühn et al
105
.  In the absence 
of IL-10, an immunosuppressive cytokine, or a functional IL-10 receptor
106
, mice develop 
intestinal inflammation.  In specific pathogen-free (SPF) conditions, inflammation is 
mild, restricted to the colon, and does not manifest until several months of age.  In 
conventionally housed mice however, inflammation is much more robust, develops more 
rapidly, and affects the upper and lower GIT.  Additionally, IL-10
-/-
 mice raised in 
conventional conditions develop several extraintestinal complications such as anemia, 
splenomegaly, and hepatitis
107
.  Considering the impact of housing conditions, IL-10
-/-
 
mice have been used to identify which particular microbial species are responsible for the 
differences in the development of inflammation.  Kullberg et al. demonstrated that H. 
hepaticus is largely responsible for the exacerbated disease in conventionally housed 
mice
108
.  Interestingly, H. hepaticus-infected IL-10
-/-
 mice raised in otherwise SPF 
conditions still fail to develop inflammation of the upper GIT.  The microbes responsible 
for this phenomenon in conventionally housed mice is unknown
107
.  The T cell-
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dependent
109
 inflammation in IL-10
-/-
 mice was originally reported to be skewed toward a 
TH1 phenotype
110
, although studies performed subsequent to the discovery of the TH17 
pathway have provided evidence that, in the absence of IL-10 signaling, IL-23 also plays 
a role in H. hepaticus-induced colitis
111
.  Thus, it is thought that the TH1 and TH17 
pathways, both of which are regulated by IL-10
112, 113
, function synergistically to promote 
T cell-dependent H. hepaticus-driven intestinal inflammation. 
The essential nature of IL-10 in the regulation of intestinal inflammatory responses has 
led to extensive study of regulatory T cells in IBD.  Toward that end, adoptive transfer of 
T cell subsets into scid mice has become another widely used model of IBD.  In this 
model, effector T cells, defined by high expression of CD45RB, induce colitis in severely 
immunodeficient (scid) mice when administered intravenously.  Alternatively, co-transfer 
of CD45RB
low
 T regulatory cells is capable of suppressing this inflammation.  Antibody 
neutralization studies have revealed that the immunosuppressive capacity of these cells is 
dependent on both IL-10 and TGF-β.  While it has not been explicitly reported as such, a 
review of the literature suggests that the transfer recipient must be infected with 
Helicobacter for the development of robust inflammation.  Thus, as in IL-10
-/-
 mice, 
while H. hepaticus is not absolutely required for the development of inflammation, it 
dramatically enhances the rapidity and severity of disease.  
Almost all mouse models of IBD require intestinal microbiota for the development of 
optimal disease
114-118
.  While the addition of H. hepaticus often exacerbates these 
models
119-122
, disease is nonetheless dependent on the presence of a background microbial 
population.  Similarly, the introduction of certain Helicobacter spp. into some wild-type 
mice with an established microbiota is capable of inducing inflammation, as in A/J mice.  
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However, IL-10
-/-
 mice fail to develop intestinal inflammation when mono-associated 
with H. hepaticus, showing the resident microbiota is essential in the induction of disease 
even in a host genetically predisposed to intestinal inflammation
123
.  These contradictions 
in the pathogenicity of Helicobacter spp. may be explained by recent studies 
demonstrating that Helicobacter spp. may act as “provocateurs” of immune responses 
against the background microbiota.  In the presence of H. bilis, gnotobiotic mice generate 
robust IgG responses against several members of a defined microbiota
79, 80
 supporting the 
notion that, while Helicobacter is itself pathogenic in susceptible strains of mice, the 
inflammation is partially in response to other microbial species as well.   
A weakness of all of the aforementioned models of IBD is the nature of the disease 
induction.  Models are either performed in a selectively or globally immunodeficient 
mouse strain, or are induced via administration of a synthetic compound not encountered 
in nature.  Thus, an immunocompetent mouse model of IBD would provide a useful 
means of dissecting the cellular and molecular factors contributing to disease 
susceptibility.  Also, the majority of mouse models of IBD are dependent on the presence 
of the adaptive immune system
91
.  As there is considerable evidence that IBD in humans 
has a basis in the recognition of microbes by cells of the innate immune system, a model 
of IBD that functions independent of the adaptive immune system is desirable.  Lastly, in 
an ideal model of IBD, inflammation would manifest in response to commensal intestinal 
microbes and would have phenotypic similarities to IBD in humans.  All of these criteria 
are met in the H. hepaticus-infected A/J mouse model of IBD. 
A/J and B6 mice are both immunocompetent strains of mice, with demonstrated 
differential susceptibility to H. hepaticus-mediated cecal inflammation.  The lack of any 
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genetic manipulation provides a more realistic comparison to human physiology.  In 
contrast to most other mouse models of IBD, H. hepaticus-induced inflammation in A/J 
mice is independent of an adaptive immune system.  While the histological appearance of 
disease is clearly (and not surprisingly) altered in A/J mice lacking functional T and B 
cells, disease persists nonetheless.  Additionally, the absence of disease in H. hepaticus-
infected B6 mice is also independent of an adaptive immune system.  Thus, as the innate 
immune system is increasingly implicated in the pathogenesis of IBD, the H. hepaticus-
infected A/J model offers a model of IBD driven by the innate immune system and its 
recognition of the gut microbiota.  This is critical in the proceeding studies as published 
reports of the role of various subsets of intestinal dendritic cells (DC) in inflammation 
have relied on in vitro stimulation using pathogens associated with disease in other organ 
systems
124
, or highly artificial adoptive transfer models
125
.  Other investigations of the 
function of intestinal DC subsets have examined physiological settings in the absence of 
inflammation
126-130
.  Thus, there is a distinct lack of knowledge regarding the role of 
intestinal DC subsets in IBD-like syndromes. 
As mentioned above, there is also convincing evidence that multiple bacterial species 
closely related to H. hepaticus induce host immune responses against commensal 
members of the intestinal microbiota.  Of note, antigen-specific IgG1 and IgG2a 
responses to commensal microbes were detected in H. bilis-infected mice, and mesenteric 
lymphocytes from H. bilis- and Brachyspira hyodysenteriae-infected mice produced 
higher levels of IFN-γ than control mice79, 80.  The extended period of latency between 
experimental inoculation with H. hepaticus and the development of histologically 
identifiable inflammation in A/J mice fits well with the concept of certain Helicobacter 
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spp. functioning as provocateurs of immune responses against microbes not normally 
capable of inducing such reactions.   
Lastly, there are considerable phenotypic similarities between H. hepaticus-infected A/J 
mice and humans affected with IBD.  Histologically, the ceca of infected A/J mice 
possess mild to marked inflammation characterized by mononuclear cells (the majority of 
which have a large nuclear:cytoplasmic ratio consistent with lymphocytes), and mild to 
moderate hyperplasia.  Inflammation is multifocal to continuous and may extend deep 
into the lamina propria but rarely into the muscularis.  The immune response in infected 
A/J mice represents a generalized innate immune response, typified by increased 
expression of several chemokines and genes involved in antigen processing, followed by 
a TH1-driven adaptive immune response, characterized by increased expression of IFN-γ 
and multiple interferon-induced genes
131
.   The immunopathogenesis of IBD is strikingly 
similar with altered expression of genes associated with the TH1 cytokine profile as well 
as more generalized acute inflammatory mediators such as TNF-α.  Interestingly, the H. 
hepaticus-infected A/J model also has certain attributes mimicking the demographics of 
human IBD.  With respect to age, A/J mice infected at weaning develop disease at 
approximately four months of age.  This corresponds to early adulthood, the age at which 
IBD is most commonly diagnosed in humans.  Regarding sex, female A/J mice develop 
more severe inflammation than male mice, and express significantly higher levels of 
several cytokines and chemokines implicated in the disease process
132
.  Similarly, there is 
a slight female predominance in Crohn’s disease, especially among women in late 
adolescence and early adulthood
133
.  Hence, the H. hepaticus-infected A/J mouse 
provides a uniquely applicable model of IBD with phenotypic and immunological 
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similarities to IBD in humans, particularly in studies examining the innate immune 
system.   
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SIGNIFICANCE OF COLITIS-ASSOCIATED COLORECTAL CANCER 
Inflammation, characterized by the accumulation of activated leukocytes in affected 
tissue, occurs in response to tissue damage of almost any cause.  In cases of acute and 
balanced inflammation, inflammation is beneficial to the host and serves to eradicate the 
insulting agent, and remove damaged cells and cellular components.  Additionally, 
inflammatory cells stimulate wound-healing via promotion of angiogenesis, collagen 
deposition, and epithelial restitution, as well as proliferation or attraction of cells 
necessary for healing such as fibroblasts and platelets.  Macrophages, a primary source of 
epidermal growth factor, platelet-derived growth factor, fibroblast growth factors 1 and 2, 
transforming growth factors α and β, IL-1, and TNF- α, are particularly critical for wound 
healing.  In cases of acute inflammation, this process wanes as infectious agents are 
eradicated and the wound is repaired.  If the causative agent is not removed however, 
chronic inflammation occurs, often to the detriment of the patient.  In this situation, 
macrophages continually attempt to remediate tissue damage and, in the process, release 
abundant reactive oxygen and nitrogen species such as peroxides and peroxynitrite.  
These molecules lead to oxidative and nitrosative stress, which are also injurious to tissue 
when present at high levels or for prolonged periods.  Additionally, chronic production of 
cytokines such as TNF-α and IL-1 can promote tumor growth via direct effects on tumor 
cells and stimulation of epithelial to mesenchymal transition
134
.  Thus, chronic 
inflammation due to a persistent insult can lead to a vicious cycle of tissue damage and 
leukocyte recruitment, all of which leads to a pro-tumorigenic environment. 
Chronic inflammation is associated with approximately 20% of human cancers
135, 136
 and 
it is now well accepted that inflammation is causally linked to cancer
137
.  This is 
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especially germane to the GIT wherein conditions such as Barrett’s esophagus138, 
infection with Helicobacter pylori
139
, and inflammatory bowel disease
140
 are primary risk 
factors for cancer of the affected organ.  While colitis-associated colorectal cancer (CAC) 
constitutes a relatively small portion of colorectal cancer (CRC) in general, IBD patients 
are among the highest risk group for developing CRC
141
, with a two- to three-fold greater 
chance of developing colorectal cancer
140
.  Critical factors affecting the risk of CAC 
include the duration, extent, and severity of inflammation
2, 140
.   
PATHOGENESIS OF COLITIS-ASSOCIATED COLORECTAL CANCER 
CAC is distinct from familial forms of colorectal cancer and sporadic colorectal cancer 
(SCC) in both presentation and molecular pathogenesis.  Clinically, CAC affects 
individuals at a younger age than SCC and there is a higher incidence of multiple 
synchronous primary lesions in CAC.  The location also varies between the two forms of 
CRC with, on average, a more proximal location noted in CAC.  Mucinous and “signet 
ring” phenotypes are also more frequently seen in CAC than in SCC, the significance of 
which remains unclear.  Regarding the molecular events leading to neoplasia, SCC 
follows a characteristic progression from an adenomatous polyp driven by genetic and 
epigenetic alterations leading to the malignant transformation of colonic epithelium.  The 
principal molecular pathways responsible for this transformation include chromosomal 
instability (CIN) and microsatellite instability (MSI), which account for approximately 85 
and 15% of sporadic CRC respectively
142
, as well as epigenetic changes in the CpG 
island methylator phenotype (CIMP).  CIN results in abnormal segregation of 
chromosomes and abnormal DNA content.  The resulting loss of heterozygosity 
frequently leads to loss of function of tumor suppressor genes such as APC and p53, the 
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former characteristically occurring early in disease progression, the latter much later.  
The MSI pathway is associated with loss of function of mismatch-repair genes which 
encode proteins responsible for the repair of DNA base-pair mismatches occurring during 
DNA replication.  While MSI can thus lead to DNA replication errors throughout the 
entire genome, certain genes containing short nucleotide repeats that are intrinsically 
unstable (such as TGFβRII) are particularly susceptible to replication errors142.  In 
contrast to SCC, CAC derives from an area of epithelial dysplasia rather than a polyp, 
and while CIN and MSI occur at roughly the same frequency as in SCC, molecular events 
follow a distinctly different progression (figure 1.1)
142
.  For example, mutations in APC 
typically occur late in the development of CAC
143, 144
, while mutations in p53, considered 
a key event in the progression from late adenoma to carcinoma in SCC, occur early in the 
development of CAC
145
.   
While a patient with IBD and a family history of CRC has approximately a two-fold 
greater risk of developing CRC than an IBD patient with no family history of CRC
146
, no 
clear genetic etiology has been attributed to CAC per se
142
.  Thus, as in IBD, there are 
likely environmental factors involved in disease risk as well.  It is well-known that 
nonsteroidal anti-inflammatory drugs decrease the risk of SCC and polyps in individuals 
with familial adenomatous polyposis (FAP), presumably due to the inhibition of 
cyclooxygenase-2, a gene induced in premalignant colonic epithelium of IBD patients.  
Additionally, nutrition is thought to play a role in risk of CRC.  In one cohort of patients 
affected with UC and demonstrating MSI in non-neoplastic colonic epithelium, folate 
levels were lower than in patients without MSI.  Dietary supplementation of folate 
resulted in changes in the pattern of microsatellite stability.  Thus, along with unknown 
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genetic factors, medication and diet (and likely other environmental factors) also affect 
individual risk of CAC in IBD patients. 
ANIMAL MODELS OF COLITIS-ASSOCIATED COLORECTAL CANCER 
One of the most commonly used and oldest models of CRC is the APC
min/+
 mouse, also 
referred to as the APC
Δ716
 or Min mouse
147
.  These mice carry a heterozygous dominant 
mutation in the Apc gene encoding a protein which modulates Wnt signal transduction 
through β-catenin, providing a model of FAP, a hereditary form of human CRC most 
often caused by mutations in Apc.  These mice were developed via random mutagenesis 
using the alkylating agent ethylnitrosourea (ENU) and are maintained on a heterozygous 
background via matings between affected males and wild-type females as mice carrying 
the mutation have shortened life spans and affected females have difficulty maintaining 
pregnancies.  Specific-pathogen-free APC
min/+ 
mice develop multiple intestinal neoplasms 
(hence Min) throughout the small and large intestines, while germ-free mice experience a 
50% reduction in tumor number leading to the model’s use in studies of the role of 
intestinal microbiota on carcinogenesis
148
. 
Regarding CAC, there are several mouse models including the Gai2
-/-
, IL-10
-/-
, IL-2/β2-
microglobulin
-/-
, and Smad3
-/-
 strains of mice.  Of note, many of these models fail to 
manifest disease unless infected, either naturally or experimentally, with certain enteric 
bacteria, typically Helicobacter hepaticus or H. bilis.  As these Helicobacter spp. do not 
cause colorectal cancer in wild-type mice, these models provide the opportunity to study 
the combined contributions of the immune system and the intestinal microbiota in 
carcinogenesis.  There are also chemically induced models of inflammatory bowel 
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disease (IBD) which are potentially useful in the study of CAC, such as the dextran 
sodium sulfate (DSS) model, performed with
149
 or without
150
 the addition of the 
carcinogen azoxymethane (AOM).  DSS, a high-weight sulfated polysaccharide, is 
administered in the drinking water and, due to its direct toxicity to crypt cells, results in a 
fairly acute loss of crypts, alterations in the microbiota, and inflammation with eventual 
development of CAC.  There are multiple doses and schedules of DSS administration 
designed to model different human disease entities.  In studies of CAC, it is commonly 
administered cyclically, e.g. 7 days on, 7 days off, etc., to mimic the remitting and 
relapsing nature of IBD.  Additionally, inbred strains of mice vary in their susceptibility 
to this model
151, 152
, allowing for studies of genetic susceptibility such as quantitative trait 
loci analyses.  The addition of AOM results in more consistent and more acute 
development of tumors than that seen with DSS alone.  Administration of AOM by itself 
also induces colorectal cancer in both rats and mice, potentially due to its effects on TGF-
β signaling153, 154, and has been used extensively in the study of potential protective 
compounds. 
The model used in the studies described in Chapter 3 is the Smad3
-/-
 mouse on a 129/Sv 
background strain
155
.   Smad3 is a component of a heterotrimeric transcription factor 
functioning downstream of TGF-β signaling.  Of note, mutations in multiple genes 
affecting the TGF-β pathway have been associated with human CAC and a loss of 
function mutation in TGF-βRII is considered a poor prognostic indicator in CAC.  Thus, 
the Smad3 mouse model of CAC provides a biologically relevant model of the human 
condition.  Inflammation and the subsequent CAC occur as a result of inoculation with H. 
bilis
156
, and, histologically, naïve mice appear completely normal.  Based on the 
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purported role of H. bilis as a provocateur of intestinal immune responses against 
commensal bacteria
79, 80
, the fact that the pathway affected by mutation in Smad3 is 
commonly affected in humans diagnosed with CAC, and the phenotypic similarities 
between CAC in Smad3
-/-
 mice and mucinous adenocarcinoma in humans, this is an ideal 
model for investigations of diagnostic biomarkers of CAC.   
A biomarker is defined as an indicator of a biological state.  For example, rather than 
directly identifying lactate dehydrogenase-elevating virus in mice, the elevation of the 
lactate dehydrogenase enzyme in peripheral blood provides a relatively accurate 
biomarker of infection.  Biomarkers can conceivably be derived from any biological 
sample and can take the form of DNA, RNA, protein, or even complex traits such as coat 
color or odor.  The development of molecular, i.e. nucleic acid-based, fecal biomarkers of 
dysplasia in mouse models of CAC will serve to refine the model and reduce the number 
of animals needed for adequate statistical power without any invasive sample acquisition.  
Additionally, diagnosis of CAC in IBD patients is classically made via colonoscopy, a 
technique fraught with unpleasant aspects and subject to many false negatives.  If 
translated to humans, the development of molecular biomarkers has the potential to 
increase patient compliance with screening recommendations put forth by the American 
Gastroenterological Association
157
 and the American College of Gastroenterology, and 
thus enhance early detection of suspect lesions and patient survival. 
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CHAPTER 2 
OVERVIEW 
Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative 
colitis (UC), affects over one million Americans and is now the second most common 
chronic inflammatory disease after rheumatoid arthritis
158
.  The most common 
manifestations are painful abdominal cramping, recurrent diarrhea, and rectal bleeding, 
however complications from the chronic inflammation can include obstructions due to 
fibrosis, fistulae necessitating surgery, nutritional deficiencies, and an increased risk of 
colorectal cancer correlating with disease duration and the extent of GI involvement
159
.   
CD is characterized by segmental, often transmural, inflammation affecting any region of 
the GIT from the oral cavity to the anus.  The inflammation is thought to be in response 
to non-pathogenic or commensal intestinal microbes, and while changes in the intestinal 
microbiota have been identified in IBD patients, no causative etiologic agent has been 
identified despite numerous attempts
74, 160-169
. While the majority of cells in the lesions of 
CD patients are T lymphocytes, a component of the adaptive immune system, mounting 
evidence implicates the response of the innate immune system to the intestinal microbiota 
as a precursor to the recruitment of T cells.  Specifically, several quantitative trait loci 
(QTL) have been identified in IBD patients encoding pattern recognition receptors 
(PRRs) responsible for recognition of bacteria, including but not limited to nucleotide-
binding oligomerization domain-containing protein 2 (Nod2)
29, 31, 170, 171
, toll-like receptor 
(TLR4), and TLR5
172-176
.  Other QTL have implicated the cytokine networks downstream 
of the recognition of the GI microbiota.  For example, mutations in the receptor for IL-23, 
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a cytokine produced by DC, may confer resistance
177, 178
 or susceptibility to CD
179-181
.  
Thus, disease susceptibility is, at least partially, determined by the sensing of GI 
microbiota by the innate immune system.   
There are myriad ways of modeling IBD in animals including chemically induced models 
such as dextran sodium sulfate (DSS)-induced colitis, genetically induced models such as 
IL-10
-/-
 mice, and microbially induced models such as H. hepaticus-infected A/JCr (A/J) 
and C57BL/6 (B6) mice.  In the latter, employed in the present studies, A/J and B6 mice 
are both colonized equivalently by H. hepaticus following gastric gavage, however the 
A/J strain of mouse develops a latent lymphocytic typhlitis following acute perturbations 
in cytokine expression whereas the B6 strain experiences only transient alterations in 
cytokine expression and no histological evidence of inflammation.  This is an extremely 
useful model for several reasons. For one, both mouse strains are immunocompetent with 
no genetic manipulations, mimicking the human condition in which known genetic 
polymorphisms account for only a portion of disease susceptibility.  While knockout and 
transgenic strains of mice have shed light on the role of specific cytokines in the 
inflammatory cascade of IBD, the pleiotropic and redundant nature of many cytokines 
makes it difficult to separate immediate effects of the addition or deletion of a single 
cytokine from downstream effects.  Secondly, the extended period of latency between 
inoculation and the development of inflammation allows for the investigation of events 
leading up to disease.  Previous studies have revealed several acute changes in cytokine 
expression in infected mice responsible for setting the stage for the eventual 
inflammation.  Thirdly, disease is induced by inoculation with H. hepaticus, providing an 
ideal microbial trigger for the initiation of disease.  The addition of H. hepaticus often 
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exacerbates other models of IBD
119-122
, though disease is almost always dependent on the 
presence of background microbiota also.  For example, IL-10
-/-
 mice fail to develop 
intestinal inflammation when mono-associated with H. hepaticus, showing that the 
resident microbiota is essential in the induction of disease even in a host genetically 
predisposed to intestinal inflammation
123
.  Similarly, the introduction of certain 
Helicobacter spp. into some WT mice with an established microbiota is capable of 
inducing inflammation, as in A/J mice.  These contradictions in the pathogenicity of 
Helicobacter spp. may be explained by findings suggesting that certain Helicobacter spp. 
act as “provocateurs” of immune responses against commensal microbiota.  In the 
presence of H. bilis, gnotobiotic mice generate robust IgG responses against several 
members of a defined flora
79, 80
 supporting the notion that, while Helicobacter is 
considered pathogenic in susceptible strains of mice, the inflammation is partially in 
response to other microbial species as well.  As IBD is likely triggered by an event or 
events that result in abnormal recognition of commensal microbes, the Helicobacter-
induced model provides an attractive means of studying this complex process.  
Lastly, similar to IBD in humans, the inflammation in H. hepaticus-infected A/J mice is 
largely driven by the innate immune system, as supported by the following findings.  
Previous studies from our laboratory have examined the expression of several 
chemokines and cytokines in the ceca of H. hepaticus- and sham-inoculated A/J and B6 
mice
131, 182
.  The immune response at 90 days PI in A/J mice is TH1-mediated, evinced by 
significant increases in the expression of IL-12/23p40, a pro-inflammatory cytokine 
produced primarily by dendritic cells (DC), and IFN-γ.  Additionally, IL-12/23p40 and 
several chemokines were found to be significantly upregulated in A/J mice by 4 days PI, 
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a time point implicating the innate immune system.  Conversely, the immune response of 
B6 mice was blunted relative to that of A/J mice, and chemokine and cytokine levels 
returned to baseline rapidly or were not elevated compared to uninfected controls, e.g., 
IL-12/23p40. The expression of these mediators is causally linked to the inflammation as 
antibody neutralization of either IL-12/23p40 or IFN-γ significantly decreases cecal 
lesion scores
131
.  As DC are the major intestinal source of IL-12/23p40, its differential 
expression at 4 days PI in susceptible and resistant mice suggests a role for DC in the 
pathogenesis of H. hepaticus-induced disease.    
While the innate immune system comprises several cell types including epithelial cells 
and natural killer (NK) cells, professional antigen-presenting cells such as dendritic cells 
(DC) represent a logical avenue of research for several reasons.  Firstly, DC are the 
primary cellular source of IL-12/23p40, the defining cytokine in H. hepaticus-infected 
A/JCr and C57BL/6 mice.  While the expression of other inflammatory cytokines is 
transiently elevated following infection of B6 mice, IL-12/23p40 is never differentially 
expressed between infected and uninfected B6 mice.  Additionally, some inflammatory 
cytokines such as IFN-γ and CXCL9 (MIG) are subject to a biphasic elevation in infected 
A/J mice, wherein expression peaks at 4 days post-inoculation (PI), diminishes to 
baseline levels, and then rises again concurrent with the development of histological 
evidence of disease.  The expression of IL-12/23p40 in A/J mice however rises acutely 
following infection with H. hepaticus and remains elevated indefinitely.  Thus, as DC are 
the main source of IL-12/23p40, it stands to reason that there is either a difference 
between A/J and B6 mice in the number of total DC or some subset of DC, or a 
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difference in the manner in which the cells in the cecum respond to some H. hepaticus-
mediated stimulus in the cecum. 
Further, it is now recognized that there are distinct subsets of DC in the gut.  It is vital to 
discern the role of each subset in exacerbating or ameliorating disease.  In mice, 
conventional intestinal DC are composed of 3 subsets, all of which are CD11c
+
.  The 
three subsets of DC are differentiated by their expression of CD8α and the integrin 
subunit CD11b, resulting in CD11c
+CD8α+CD11b- (CD8α+), CD11c+CD8α-CD11b+ 
(CD11b
+
), or CD11c
+CD8α-CD11b- (double negative, DN) DC in the small intestines and 
colon.  To the author’s knowledge, no studies have examined the proportions of these DC 
subsets in the cecum and, in fact, there are no reports of the number or function of DC in 
the cecum of any species (based on a search of the National Library of Medicine using 
the medical subject headings “dendritic cells” and “cecum”).  Several studies have 
demonstrated characteristic responses of each subset in other regions of the gut.  CD11b
+
 
DC are the principal subset responsible for inducing cross-tolerance to endogenous 
intestinal antigens
183.  Only these cells, and not the CD8α+ or DN subsets, produce 
abundant IL-10 upon stimulation with either CD40L or Staphylococcus aureus and IFN-
γ124.  In turn, T cells cultured with the CD11b+ subset produce significantly more IL-10 
and IL-4 than T cells cultured with CD8α+ or DN DC.  Additionally, in mice in which the 
CD11b
+
 subset has been genetically inactivated, oral tolerance is abolished while DC 
maturation and antigen-specific immune activation appears unaffected
184
.  Thus, the 
CD11b
+
 subset of DC appears to have an immunoregulatory role in intestinal 
homeostasis, in response to both endogenous and bacterial antigens.  The CD8α+ and DN 
DC subsets behave quite differently than the CD11b
+
 subset.  In vitro studies indicate that 
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both subsets, but particularly CD8α+ DC, produce IL-12p70 following stimulation with 
pathogenic microbes or CD40L
124, 128
.  Similarly, the DN subset was shown to be 
responsible for constitutive IL-12/23p40 production in the terminal ileum
130
.  While there 
is evidence that DN DC are also capable of cross-presenting antigen in the intestine
185
, 
this results in a TH1-biased immune response rather than tolerance as in the case of 
CD11b
+
 DC-mediated cross-presentation
183
.  Thus, substantial evidence supports a role 
for CD8α+ and DN DC in the induction of mucosal immune responses.   
Considering the above, our overall hypothesis is that the inflammation induced in H. 
hepaticus-infected A/J mice is due to differences in the composition of the intestinal DC 
populations or the responsiveness of one or more subsets of intestinal DC to some 
microbial stimulus.  Specifically, we hypothesize the disease is due to an excessive 
number (either absolute or relative) of CD8α+ DC in A/J mice, and that cecal cells will 
produce greater amounts of IL-12/23p40 and other inflammatory cytokines in response to 
microbial stimulation in A/J mice relative to B6 mice. 
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MATERIALS & METHODS 
Bacteria and Cultivation.  A Helicobacter hepaticus isolate (MU-94) was obtained from 
an endemically infected mouse colony using a previously described culture technique
186
.  
The isolate was identified as H. hepaticus based on ultrastructural morphology, 
biochemical characteristics, and sequence analysis of the 16s rRNA gene
187
.  For 
inoculation, H. hepaticus cultures were grown in 5 mL of Brucella broth (Becton 
Dickinson, Franklin Lakes, NJ) supplemented with 5% fetal calf serum (Sigma-Aldrich 
Co., St. Louis, MO) and overlaid on blood agar plates and incubated for 24 to 48 hours at 
37 °C in a microaerobic environment containing 90% N2, 5% H2, and 5% CO2. 
Animals.  All studies were performed in accordance with the Guide for the Care and Use 
of Laboratory Animals and were approved by the University of Missouri Institutional 
Animal Care and Use Committee.  Weanling A/JCr and C57BL/6Cr mice were obtained 
from the Frederick Cancer Research and Development Center, Frederick, MD.   Six week 
old B6.129S6-Rag2
tm1Fwa
 mice were purchased from Taconic, Hudson, NY.  All mice 
were confirmed to be free of adventitious viruses, parasites, and pathogenic enteric and 
respiratory bacteria, including all known murine Helicobacter spp.  Three to four week 
old mice were inoculated with 10
8
 H. hepaticus organisms in 0.5 mL Brucella broth, or 
an equivalent volume of sterile broth, via gastric gavage.  Separate cohorts of mice were 
used for each study including flow cytometry (n = 7 to 11 with 5 to 10 mice pooled per 
data point) and ex vivo stimulation, ELISA and microbead fluorescent immunoassays (n 
= 4 to 8 groups of 5 mice pooled per data point). Mice were group-housed according to 
infection status in autoclaved microisolator cages and were provided autoclaved food and 
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water.  All manipulations and sample collections were performed in a biosafety hood.  
Mice were euthanized at 0 to 90 days PI via inhaled overdose of CO2. 
Tissue Digestion and Cell Isolation.  For flow cytometric and ex vivo stimulation 
experiments, cells were pooled from 5 to 10 mice per data point.  Cecal tissue was 
collected using aseptic technique immediately following euthanasia.  Ceca were incised 
longitudinally and opened such that the mucosal surface was exposed.  Cecal tissue was 
then rinsed vigorously with saline to remove all gross cecal contents.  Tissue was then 
minced with a scalpel blade and placed immediately into a 50 mL conical tube containing 
Hank’s Balanced Salt Solution (HBSS) supplemented with 5% fetal bovine serum (FBS), 
0.05 mM ethylenediaminetetraacetic acid (EDTA), 0.6 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 15 µg/mL dithiothreitol (DTT), 100 i.u./mL 
penicillin, 100 µg/mL streptomycin, and 0.25 µg/mL amphotericin.  Tissue was then 
washed several times and filtered through 100- and 70-µm nylon mesh filters to remove 
remaining bacteria and ingesta.  Tissue pieces were then centrifuged at 400×g for 10 
minutes before aspirating the supernatant entirely and reconstituting in Roswell Park 
Memorial Institute (RPMI) buffer supplemented with 10% FBS, 0.6 mM HEPES, and the 
antimicrobials added to HBSS above.  Tissue was then digested in a 50 mL conical tube 
containing supplemented RPMI buffer and approximately 1 mg/mL collagenase D for 
two hours at 37°C in a shaking incubator (C24KC refrigerated shaker incubator, New 
Brunswick Scientific, Edison, NJ).  Digested cecal tissue was then filtered through a 70-
µm nylon mesh filter and the flow-through collected.  Cells were then washed repeatedly 
and filtered through progressively smaller filter pore sizes to remove clumps of epithelial 
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cells and remaining pieces of ingesta.  Cells in suspension were then counted using a 
hemocytometer on an inverted light microscope. 
Flow Cytometry.  All flow cytometry data was collected on a CyAn ADP flow 
cytometer (Becton Dickinson) and analyzed using Summit 5.2 analysis software.  All 
antibody staining was performed in the presence of Fc block (purified rat IgG2b anti-
mouse CD16/CD32 monoclonal antibody, clone 2.4G2)(BD Biosciences) to prevent 
nonspecific, Fc-mediated adherence of antibodies to mouse Fc receptors.  The following 
were purchased from BD Biosciences: hamster IgG1 anti-mouse CD11c-PE (clone HL3), 
hamster IgG1 anti-TNP-KLH-PE (clone G235-2356), rat IgG2a anti-mouse CD8α-APC 
(clone 53-6.7), and rat IgG2b anti-TNP-KLH-FITC (clone A95-1).  The following were 
purchased from Abcam: rat IgG2a anti-mouse CD11b (clone 3A33) and rat IgG2a anti-
KLH (clone RTK2758).  Briefly, Cells were incubated with Fc block at 4°C for 30 
minutes prior to addition of target antibodies.  Cells were then incubated an additional 
hour at 4°C before washing the cells twice and resuspending in sterile PBS.   
Enzyme-linked Immunsorbent Assay and Microbead Fluorescent Immunoassay.  
Cells isolated from cecal tissue were plated on 24-well plates at a concentration of 5×10
5
 
cells in one mL of supplemented RPMI buffer.  Cells were allowed to rest for 
approximately 18 hours, primed with recombinant mouse IFN-γ (Reprokine Ltd., Valley 
Cottage, NY) at 10 ng/mL for two hours and then stimulated with live H. hepaticus 
culture (approximately 5×10
7 
CFU/mL), 500 ng/mL purified E. coli K12 
lipopolysaccharide, or 20 µL Brucella broth as a negative control.  Stimulated cells were 
then incubated at 37°C for 24 hours before collecting the supernatant for analysis.  
Cytokines and chemokines, including G-CSF, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, 
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IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, IL-15, IL-17, IP-10, KC, MCP-1, MIP-1α, 
RANTES, and TNF-α, were measured using either RayBio® Mouse IL-12 (p40/p70) 
ELISA kit (RayBiotech, Inc. Norcross, GA) or Milliplex® MAP Mouse 
Cytokine/Chemokine Kit (Millipore Corp., Billerica, MA), following the manufacturer’s 
instructions, using a BioTek® ELx800 plate reader (Biotek, Winooski, VT) or Luminex 
® 100 Analyzer (Luminex Corp., Austin, TX) respectively.  For ELISA analysis, cells 
were added to 96-well plates coated with anti-mouse IL-12 capture antibodies, incubated 
and washed.  Biotinylated secondary antibodies were then added, followed by 
streptavidin and then TMB for visualization of plate-bound IL-12.  For MFI analysis, cell 
culture supernatants were added to a mixture of unique microbead sets, each set 
containing specific internal dyes and coated with capture antibodies against one analyte.  
Following incubation, a set of detection antibodies against each analyte was added, 
followed by streptavidin-phycoerythrin (SA-PE).  Labeled beads were passed in a sheath 
fluid by a series of lasers and detection filters in order to discern the identity of each 
microbead (i.e. the specificity of the antibody bound to its surface) as it passed, as well as 
the relative intensity of SA-PE bound to the microbead, termed the median fluorescent 
intensity.  Both kits provided a mixture of recombinant standards for each analyte 
measured which were serially diluted and analyzed alongside unknowns to generate a 
standard curve.  For both ELISA and MFI, all samples including standards were analyzed 
in duplicate. 
Generation of Congenic Mice.  Female B6.129S6-Rag2
tm1Fwa
 mice, purchased from 
Taconic, were bred to male wild type A/JCr mice to generate heterozygous pups.  Male 
pups were backcrossed to wild type mice of either recipient strain to fix the Y 
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chromosome.  Each generation thereafter was screened via PCR for the mutated allele.  
Mice carrying the mutation were then screened via microsatellite analysis to determine 
the contribution of each parent and select optimal breeders for the subsequent generation.  
After sufficient backcrosses to yield mice greater than 99% A/J based on microsatellite 
analysis, mice were intercrossed to generate homozygous mutants on the A/JCr 
background. 
129/SvEv-Batf3
tm1Kmm
 mice (kindly provided by Dr. Kenneth Murphy from Washington 
University in St. Louis, MO) were bred to wild type A/JCr mice, and male pups 
heterozygous for the mutated Batf3 were then backcrossed to A/JCr mice in order to fix 
the Y chromosome.  Offspring from this and all subsequent generations were then 
screened for the mutation via PCR and heterozygous females were backcrossed 6 
additional times to A/JCr males.  Breeders for the last three backcrosses were selected 
using marker-assisted breeder selection based on genome-wide analysis of a panel of 65 
microsatellites representing all chromosomes (3130xl Genetic Analyzer, Applied 
Biosystems, Grand Island, NY).  Briefly, in each generation, multiplexed PCR analysis of 
65 microsatellites specific for either A/J or 129/SvEv mice was used to identify the 
optimal breeders for the subsequent backcross, i.e. those mice carrying the greatest 
proportion of recipient microsatellite markers.  This breeding strategy was used for 
backcrosses 5 through 7, followed by a final brother × sister intercross of heterozygous 
pups to produce homozygous A/JCr.129-Batf3
tm1Kmm
 mice. 
DNA Extraction.  DNA was isolated from tail-snips or fecal pellets for genotyping and 
confirmation of infection status PCRs respectively using DNeasy kit according to 
manufacturer’s instruction.  The quantity and quality of DNA was assessed by measuring 
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the absorbance at 260 nm and 280 nm (Nanodrop-1000 Spectrophotometer, Nanodrop, 
Wilmington, DE) 
Polymerase Chain Reaction.  PCRs used for genotyping and confirmation of infection 
status were performed in an Applied Biosystems 2720 thermal cycler.  All PCR products 
were visualized using a Qiaxcel Genotyping assays included a two-primer assay designed 
to detect the Neo cassette and a three-primer assay designed to differentiate wild-type, 
heterozygous, and homozygous knock-out mice.  Primer sequences and cycling 
parameters for the two reactions were kindly provided by Dr. Elizabeth Bryda 
(University of Missouri) and Dr. Kenneth Murphy (Washington University) respectively.  
Primers for the two-primer genotyping assay are: 
CATTCGACCACCAAGCGAAACATC (Neo F) and 
ATATCACGGGTAGCCAACGCTATG (Neo R).  Each 20 µL reaction contained 1 µL 
of DNA template, 2 µL per reaction of 10× buffer containing MgCl2 (Roche), 1.25 mM 
dNTP (Promega), 10 µM of Neo F and Neo R primers, 5 U/µL Taq Fast Start polymerase 
(Roche), and milliQ deionized water.  Thermal cycling consisted of initial denaturation at 
95°C for 5 minutes followed by 35 cycles of denaturation at 94°C for 30 seconds, 
annealing at 68°C for 30 seconds, and extension at 72°C for 1 minute.  The expected 
product is 289 bp in length.  Primers for the three-primer assay are: 
TGCTATGCACAAACCACAAACC (p21 F), GTTGTGAGTCGAAACCACGC (p21 
R), and CGTTGGCTACCCGTGATATTGC (Neo R).  Each 20 µL reaction contained 1 
µL of DNA template, 4 µL per reaction of 5× Green GoTaq Flexi buffer (Promega), 25 
mM MgCl2, 2.5 mM dNTP, 10 µM of p21 F, p21 R, and Neo R primers, 5 U/µL GoTaq 
polymerase (Promega), and milliQ deionized water.  Thermal cycling consisted of initial 
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denaturation at 95°C for 4 minutes followed by 35 cycles of denaturation at 54°C for 30 
seconds, annealing at 58°C for 30 seconds, and extension at 72°C for 52 seconds.  The 
expected products are 288 and 750 bp in length for wild-type and knock-out DNA 
respectively. 
STATISTICAL ANALYSES 
All statistical analyses were performed using SigmaPlot 12.0 (SPSS Inc., Chicago, IL). 
Dendritic Cell Numbers.  Cells isolated from the cecum of naïve, 4 day post-inoculation 
(PI), and 90 day PI A/JCr and C57BL/6Cr mice were enumerated using an improved 
Neubauer hemocytometer on a Nikon model TMS inverted microscope (Nikon Inc., 
Melville, NY).  Multi-channel flow cytometry was used to measure the frequency of cells 
expressing CD11c, CD8α, and CD11b.  The significance of differences in the percentage 
or absolute number of cells expressing one or more surface markers between strains at 
each time point was determined using a Student’s t-test or Mann Whitney rank sum test 
for parametric and nonparametric data respectively, with significance being p ≤ 0.05. 
Ex vivo Cytokine Production.  ELISA was used to measure IL-12 (p40 and p70).  
Microbead fluorescent immunoassays were used to measure G-CSF, GM-CSF, IFN-γ, 
IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-15, IL-17, IP-
10, KC, MCP-1, MIP-1α, RANTES, and TNF-α production by equivalent numbers of 
cecal cells isolated from naïve, 4 day post-inoculation (PI), and 90 day PI A/JCr and 
C57BL/6Cr mice and stimulated ex vivo with live H. hepaticus, E. coli (K12) 
lipopolysaccharide, or culture medium (control).  The significance of differences in mean 
cytokine/chemokine production between strains at each time point and for each stimulus 
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was determined using a two-way ANOVA and Dunnett post hoc analysis with 
significance being p ≤ 0.05. 
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RESULTS 
Influence of the Adaptive Immune System on H. hepaticus-induced Inflammation.  
To confirm the central role of the innate immune system in both resistance and 
susceptibility to H. hepaticus-induced inflammation, Rag2 (recombinase-activating gene 
2)-deficient mice lacking a functional adaptive immune system on both background 
strains were inoculated with H. hepaticus.  Similar to WT B6 mice, Rag2
-/-
 B6 mice 
develop no inflammation following infection with H. hepaticus, suggesting that the 
adaptive immune system is not required for resistance to H. hepaticus-induced cecal 
inflammation.  In Rag2-deficient A/J mice however, H. hepaticus induces a severe 
proliferative typhlitis with dysplastic epithelial changes, accompanied by a mononuclear 
cell infiltrate (figure 2.1).  Thus, while the nature of the inflammation differs in the 
absence of an adaptive immune system, H. hepaticus continues to induce mucosal 
inflammation in A/J mice lacking functional T and B cells.  This, along with the rapidity 
and nature of the mucosal immune response, strongly suggests that H. hepaticus-induced 
inflammation in A/J mice is driven by a cell of the innate immune system. 
Number of Dendritic Cells in Cecum of Naïve and Infected A/J and B6 Mice.   To 
evaluate the role of CD8α+ DC in H. hepaticus-mediated intestinal inflammation, we first 
examined the overall cellularity of the cecum of naïve weanling A/J and B6 mice to 
determine if there are differences between the two strains in the overall cellularity or the 
total number of DC, as defined by expression of high levels of the pan-DC marker 
CD11c.  Using collagenase-digested pooled cecal tissue, an average of 3.39×10
5
 and 
2.07×10
5
 lamina propria cells were recovered per mouse from naïve A/J and B6 mice 
respectively (p < 0.05) (figure 2.2A).  Similarly, there was a significant difference 
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between mouse strains in the percentage of lamina propria cells (LPC) expressing high 
levels of CD11c (consistent with a DC phenotype), as well as the absolute number of DC 
in the cecum.  In naïve A/J mice, an average of 2.29% of LPC, or 7.77×10
3
 cells per 
mouse, was identified as DC compared to 1.67% of LPC, or 3.46×10
3
 cells per mouse, in 
B6 mice (p < 0.05) (figure 2.2B).  Thus, prior to inoculation with H. hepaticus, the ceca 
of A/J mice have greater overall cellularity, and a greater number of DC, professional 
antigen-presenting cells. 
As our hypothesis is that naïve A/J mice have either higher total numbers, or proportion, 
of CD8α+ DC in the cecum than naïve B6 mice, we next examined the numbers of the 
various subsets of intestinal DC in both strains using the gating strategy depicted in 
figure 2.3.  Briefly, we first gated on live cells considered CD11c
+
, and then analyzed the 
expression of CD8α and CD11b, resulting in CD8α+CD11b- (CD8α+ DC), CD8α-CD11b+ 
(CD11b
+
 DC), CD8α-CD11b- (double negative or DN DC), and surprisingly, a previously 
unreported CD8α+CD11b+ (double positive or DP DC).  While the relative proportions of 
DC comprising these categories did not differ significantly between A/J and B6 mice, 
there were significantly greater numbers of CD8α+ DC (mean 364 versus 88 per mouse), 
CD11b
+  
DC (mean 3202 versus 1401 per mouse), and DN DC (mean 3432 versus 1595 
per mouse) in A/J mice relative to B6 mice (p < 0.05) (figure 2.4).  There was no 
difference detected between strains in the number of DP DC.  As disease susceptibility 
may also be due to an imbalance between DC subsets with opposing functions, the ratio 
of CD8α+ DC to CD11b+ DC was also determined.  There was no significant difference 
between A/J and B6 mice in this ratio although there was a trend toward a greater 
proportion of pro-inflammatory CD8α+ DC relative to CD11b+ DC in A/J mice (0.20 in 
42 
 
A/J compared to 0.13 in B6 mice).  Collectively, these results indicate that there are 
greater numbers of multiple subsets of cecal DC in naïve A/J mice, including those 
considered both pro- and anti-inflammatory.   
To determine if DC subsets are differentially recruited to the cecal lamina propria of A/J 
and B6 mice, we next evaluated the cellular composition of the cecum in mice acutely 
infected with H. hepaticus.  At four days post-inoculation (4d PI), when expression of IL-
12/23p40 is peaking in A/J mice, there was again a significantly greater number of cells 
overall in A/J mice than in B6 mice (figure 2.2A).  Similarly, as in naïve mice, the 
percentage and absolute number of cells expressing CD11c was significantly greater in 
4d PI A/J mice when compared to B6 mice (p < 0.05) (figure 2.2B).  While the overall 
cellularity of the cecal lamina propria increased only slightly in both strains of mice 
between the naïve and 4d PI time points, the number of DC increased substantially in 
both strains.  In A/J mice this increase in the number of cecal DC by 4d PI achieved 
significance, going from a median number of 6,455 DC to 17,045 DC.  Thus, in both 
mouse strains, DC were recruited to the LP following infection with H. hepaticus. 
Regarding the subsets of DC in the cecum at 4d PI, there were still significant differences 
between A/J and B6 mice in the numbers of CD8α+ and DN DC (p < 0.05); however, the 
difference in the number of CD11b
+
 DC was no longer statistically significant (figure 
2.5).  This is reflected by a comparison within each mouse strain of the numbers of each 
subset isolated prior to, and 4 days after, inoculation with H. hepaticus.  In A/J mice, 
there were significant differences between the naïve and 4d PI time points in the CD8α+ 
and DN DC subsets only.  In B6 mice, there was no statistically significant difference 
between the naïve and 4d PI time points in the level of any of the subsets.  Collectively, 
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these data indicate that while there are higher numbers of both pro- and anti-
inflammatory subsets of DC in naïve A/J mice relative to B6 mice, the pro-inflammatory 
subsets are also recruited at a greater rate to the cecal lamina propria in A/J mice 
following experimental infection with H. hepaticus.  
At 90 days PI (90d PI), the time point at which inflammation has developed in A/J mice, 
there was a significant difference between mouse strains in the overall cellularity of the 
cecum (p < 0.05) as expected (figure 2.2A).  H. hepaticus-infected A/J mice typically 
have moderate to marked lymphocytic infiltration of the lamina propria by 90d PI.   
Surprisingly however no difference was detected between strains in either the percentage 
or total number of cells expressing CD11c (figure 2.2B).  Additionally, examination of 
the subsets of DC revealed a trend toward greater numbers of all four subsets of DC in 
A/J mice relative to B6 mice.  However, the differences between strains did not reach 
statistical significance for any of the DC subsets (figure 2.6).  When comparing the 
relative numbers of each DC subset in 4d PI and 90d PI tissue within each mouse strain, 
the only difference detected was a significant increase in the number of CD11b
+
 DC in 
A/J mice.  Taken together, these data demonstrate that there are disparities in the numbers 
of both pro- and anti-inflammatory DC subsets in naïve weanling A/J and B6 mice, that 
pro-inflammatory DC subsets are preferentially recruited to the cecum in A/J mice, and 
that differences in the numbers of DC subsets are no longer evident by the time at which 
cells of the adaptive immune system have infiltrated the tissue. 
Response of Cecal Dendritic Cells to ex vivo Stimulation.  While the results of the 
above flow cytometric experiments suggest that greater numbers of CD8α+ and DN DC 
may play a role in the cecal inflammation induced by H. hepaticus in A/J mice, there is 
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also the possibility that disease susceptibility is due to excessive production of pro-
inflammatory cytokines in A/J mice.  To test the hypothesis that cells isolated from the 
cecum of A/J mice will produce greater quantities of inflammatory cytokines and 
chemokines than equivalent numbers of cells isolated from B6 mice, cells were isolated 
from the ceca of naïve, 4d PI, and 90d PI mice, plated at 5×10
5
 cells/mL and then 
stimulated ex vivo with 100 ng/mL recombinant mouse IFN-γ followed by 1 ng/mL E. 
coli LPS or 1×10
6
 CFU H. hepaticus.  Negative control cultures received 20 µL cell 
culture media.  After 24 hours, culture media was then collected for evaluation of 
cytokine production via MFI or ELISA. 
Regarding production of IL-12/23p40, cells isolated from the cecum of naïve A/J 
produced significantly greater amounts than cells from naïve B6, as determined by two-
way ANOVA with Dunnett post hoc comparisons.  Cell cultures isolated from naïve A/J 
mice contained significantly greater amounts of IL-12/23p40 at a basal level and when 
stimulated with H. hepaticus or LPS (figure 2.7).  There was however no difference 
within either mouse strain in the level of IL-12/23p40 produced between stimulated and 
unstimulated cells.  Thus, while there is differential production of IL-12/23p40 by cells 
collected from naïve A/J and B6 mice,  this difference is independent of inflammatory 
stimulus, including LPS and H. hepaticus, suggesting that cells from naïve A/J mice are 
particularly prone to IL-12/23p40 production even in the absence of overt inflammatory 
stimuli. 
No differences were detected between cells isolated from naïve A/J and B6 mice in the 
production of any other inflammatory cytokines or chemokines examined including IL-6, 
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TNF-α, and IL-1β.  Thus, in agreement with the work of Myles et al., IL-12/23p40 
appears to be a canonical cytokine in H. hepaticus-induced intestinal inflammation. 
To determine if acute infection with H. hepaticus affects the response of cells to ex vivo 
challenge with H. hepaticus or LPS, we isolated cells from the cecal lamina propria of 4d 
PI A/J and B6 mice and stimulated as described above.  In contrast to the response of 
cells from naïve mice, there was not a significant difference in the production of IL-
12/23p40 in cells from 4d PI A/J and B6 mice (figure 2.8A), despite a trend toward 
overall greater production in A/J cells.  As before, the level of cytokine production was 
unaffected by the stimulus added.  Of note, cytokine production by cells from both A/J 
and B6 mice was substantially higher than that seen in experiments using cells from naïve 
mice.  Mean IL-12/23p40 production increased from 125.00 ng/µL in naïve A/J mice to 
369.79 ng/µL in 4d PI A/J, and from 64.47 ng/µL in naïve B6 mice to 273.50 ng/µL in 4d 
PI B6 mice.  Thus, cecal cells from infected mice of both strains produce substantially 
greater amounts of IL-12/23p40. 
Other inflammatory factors however were produced in significantly greater quantities by 
cells from 4d PI A/J mice relative to 4d PI B6 mice, including TNF-α (figure 2.8B), 
CXCL10 (interferon-γ induced protein 10, IP-10) (figure 2.8C), and CCL5 (regulated 
and normal T cell expressed and secreted, RANTES)(figure 2.8D).  When comparing 
stimuli individually between mouse strains, the production of TNF-α by cells from A/J 
mice was significantly greater at a basal level, as well as when stimulated with H. 
hepaticus or LPS.  Differential production of CXCL10 and CCL5 followed similar 
patterns and achieved significance in both untreated controls and in cultures stimulated 
with H. hepaticus, suggesting that these chemokines may be critical factors in the 
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attraction of other leukocytes in H. hepaticus-mediated inflammation.  There was no 
significant difference detected in the production of any of the other cytokines or 
chemokines analyzed. 
To assess the effect of chronic infection with H. hepaticus on cytokine production, we 
next performed similar experiments using cells isolated from 90d PI A/J and B6 mice.  
As in the experiments using cells from 4d PI mice, there was no difference in the 
production of IL-12/23p40 with mean levels of 132.78 and 135.88 ng/µL in A/J and B6 
respectively (figure 2.9A).  There was also no difference detected in either strain 
between the stimulated and control cultures.  Taken in the context of the above data, cells 
from A/J mice appear to have a propensity toward exaggerated IL-12/23p40 production, 
independent of stimuli, early in life, and that following acute and chronic infection with 
H. hepaticus, the two mouse strains tend to normalize in their production of that cytokine, 
but respond differentially in their production of other inflammatory mediators. 
Similarly, IP-10, shown to be differentially produced in cells collected from 4d PI A/J 
and B6 mice, tended to normalize in both strains and returned to levels similar to those 
seen in cells from naïve mice (figure 2.9C).     
Production of TNF-α and CCL5 (RANTES) however, was largely undetectable in cell 
culture supernatants from 90d PI B6 mice and thus maintained the differential expression 
seen in cells derived from 4d PI mice.  Analysis of individual stimuli revealed significant 
differences in TNF-α production between mouse strains when stimulated with H. 
hepaticus or LPS (figures 2.9B).  Analysis of CCL5 production detected significant 
differences between strains in only H. hepaticus-treated cell cultures, despite a trend 
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toward greater production in cells from A/J mice in all treatment groups (figure 2.9D).  
Thus TNF-α, and potentially CCL5, are produced at greater levels in cells collected from 
A/J mice acutely or chronically infected with H. hepaticus, when stimulated ex vivo with 
either H. hepaticus or LPS. 
Surprisingly, there was also significantly greater production of certain inflammatory 
factors including CXCL1 (also called Groα and Neutrophil-activating factor-3) (figure 
2.10A), CCL2 (monocyte chemotactic protein-1, MCP-1) (figure 2.10B), and IL-6 in cell 
cultures of 90d PI B6 mice (figure 2.10C).  The production of CXCL1, a chemokine 
primarily attractant to neutrophils, was significantly greater in 90d PI B6 cell culture in 
only H. hepaticus-treated cultures.  Of note, CXCL1 was dramatically elevated in both 
mouse strains relative to that produced in cell cultures from naïve and 4d PI mice.  
Alternatively, CCL2 production was significantly higher in untreated cultures of 90d PI 
B6, however no significant difference was detected between strains in the H. hepaticus- 
and LPS-stimulated cells.  IL-6 was produced in greater amounts in the untreated and H. 
hepaticus-treated B6 cells, but not the LPS-treated cells.   
Collectively, these data confirm that IL-12/23p40 is differentially secreted by cecal cells 
of mouse strains considered susceptible and resistant to H. hepaticus-mediated intestinal 
inflammation.  The data also demonstrate that, ex vivo, differential production of IL-
12/23p40 exists in naïve weanling mice, but production then tends to normalize between 
strains thereafter.  We have also shown that cell cultures from the ceca of 4d PI A/J mice 
produce significantly greater amounts of other innate inflammatory mediators including 
TNF-α, CXCL10, and CCL5 at a basal level, when compared to cell cultures derived 
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from B6 mice.  In the case of TNF-α and CCL5, this relatively greater production persists 
until 90d PI, the time by which inflammation develops.   
Taken in the context of which DC subsets are present in the cecum of the two mouse 
strains prior to and four days after inoculation, it does not appear that the heretofore 
unidentified CD8α+CD11b+ (double-positive, DP) are involved in the differential 
expression of these inflammatory mediators, as this subset of DCs is present in equivalent 
numbers between strains.  While both the CD8α+ and DN subsets, known to produce IL-
12/23p40 in conjunction with IL-12p35 and IL-23p19 respectively, are present in 
significantly greater numbers in A/J mice, it is reasonable to believe that the CD8α+ 
subset is responsible for initiating the TH1-mediated inflammatory cascade underlying H. 
hepaticus-mediated chronic inflammation. 
Generation of A/J.129-Batf3
tm1Kmm
 mice lacking CD8α+ Dendritic Cells.   
Lastly, we aimed to develop a method for use in future studies of evaluating the 
physiological significance of CD8α+ DC in H. hepaticus-induced inflammation.  
Elimination of DC in vivo at the outset of these studies was restricted to the CD11c-DTR 
mouse described by Jung et al.
188
.  This technique is less than ideal for our purposes as it 
would eliminate all DC, not just the CD8α+ subset.  Recently however, a novel knockout 
mouse deficient in the transcription factor Batf3 was created and characterized as being 
deficient in CD8α+ DC189, yet possessing normal numbers of other DC subsets, CD4+ and 
CD8
+
 T cells, and B cells.  The mouse strain was however generated on a 129/SvEv 
background, historically shown to be of intermediate susceptibility to H. hepaticus-
mediated inflammation.  Thus, we endeavored to transfer the mutation to the fully 
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susceptible A/J mouse strain to assess the role in vivo of CD8α+ DC, via congenic 
A/JCr.129- Batf3
tm1Kmm
 mice. 
129/SvEv-Batf3
tm1Kmm
 (Batf3
-/-
) mice and the genotyping protocol were obtained from the 
lab of Dr. Kenneth Murphy.  Batf3
-/-
 mice were first bred to wild type (WT) A/J mice to 
generate heterozygous pups.  Male pups were selected for the first backcross to WT A/J 
mice in order to fix the Y chromosome in subsequent generations.  Pups generated from 
this and all subsequent backcrosses were first genotyped for the presence of the mutant 
Batf3 allele to select female breeders for the next mating.  Thus, we opted to utilize an 
established PCR protocol to screen for the presence of the Neo cassette used in the 
creation of the original Batf3
-/-
 mice to differentiate WT from heterozygous pups.  For the 
next four backcrosses, female pups positive the Neo cassette were backcrossed to WT A/J 
males.  Several Neo
+
 potential breeders from the N4 mating were then genotyped using a 
panel of 81 microsatellite markers, ranging from 7 to 9 markers per chromosome, capable 
of differentiating between A/J and 129 mice, i.e. marker-assisted congenics.  This 
method, used to select breeders from all subsequent litters, allowed for optimization of 
breeder selection by selecting pups with A/J markers flanking the mutated Batf3 allele, 
and discerning those pups possessing the most “A/J-like” genome overall.  Following 
three additional backcrosses, heterozygous pups estimated to be 99% A/J were 
intercrossed to generate homozygous Batf3
-/-
 mice on an A/J background.  To genotype 
these pups, two PCR assays were performed: the Neo PCR protocol to identify pups 
harboring the mutated allele, and the protocol supplied by the laboratory donating the 
mice, to identify mice lacking the WT allele.  Using the combined results of the two 
assays, each performed in duplicate, we were able to identify several male and female 
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homozygous Batf3
-/-
 mice to be used in establishing a breeding colony of A/JCr.129- 
Batf3
tm1Kmm
 mice. 
To confirm that these mice maintained the phenotype described by Hildner et al., flow 
cytometry was used to compare WT A/J, Batf3
+/-
, and Batf3
-/-
 mice.  Indeed, Batf3
-/- 
mice 
are completely lacking a CD11c
+CD8α+ population in both the cecum and spleen, 
indicating that these mice are indeed lacking CD8α+ DC.  Chronic infection studies 
comparing these and WT A/J mice are underway and will provide direct evidence of the 
physiological role of CD8α+ DC in H. hepaticus-induced typhlitis. 
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DISCUSSION 
It has become clear that there are several different types of DC in the mucosal immune 
system, distinct from the DC found in the periphery, and each with its own phenotype 
and function.  In the gut, these cells are distinguished by the presence or absence of three 
different surface markers, CD11c, CD11b, and CD8αα, a homodimer formed of two 
CD8α subunits.  CD11c serves as a universal marker for all conventional DC subsets, 
while CD11b and CD8α are thought to be expressed in a mutually exclusive manner.  
Additionally, there is a “double-negative” (DN) DC subset expressing neither CD11b nor 
CD8α.  While the CD11b+ subset has consistently been detected as the predominant 
subset in all regions of the GIT, the CD8α+ subset appears at differing frequencies 
depending on the region of the GIT examined.  To date, no studies have examined the DC 
subsets present in the mouse cecum. 
Several studies have elucidated the function of the various DC subsets in the GIT.  While 
CD8α+ and DN DC are prone to the production of IL-12 and/or IL-23190-196, CD11b+ DC 
express greater levels of immunosuppressive IL-10 and TGF-β193, 194, 197, 198.  While these 
inclinations have been documented in controlled ex vivo environments, the characteristic 
function of each subset in vivo may result from their location in the LP, as each DC 
subset resides in a specific subanatomic location within the PP.  For example, the 
CD11b
+
 subset is situated directly beneath the follicle-associated epithelium (FAE) and 
in the subepithelial dome region, putting these cells in closer proximity to the commensal 
bacteria within the lumen of the GIT.  Notably, this subset is also in close proximity to 
the epithelium which is integral in the suppression of DC responses to certain 
inflammatory stimuli via thymic stromal lymphopoietin and other factors
199-202
.  
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Alternatively, CD8α+ DC reside primarily in the T cell-rich interfollicular regions of PP.  
Thus, the reported production of IL-12 by this DC subset is consistent with the dominant 
TH1 profile seen in physiological inflammation
203
, and the response to pathogenic 
microbes may reflect the quantity, rather than quality, of cytokine produced.  
Additionally, attempts to convert one subset into another using various cytokines and 
growth factors have proven universally unsuccessful suggesting that the CD8α+, CD11b+, 
and DN DC are terminally differentiated subsets and not just developmental stages of 
DC
197, 204
. 
Predictably, the DC subsets home to their individual niches via chemokine gradients and 
the differential expression of specific chemokine receptors.  All three subsets are 
attracted to PP and the LP by CCL19 and CCL21 via CCR7 expressed on all CD11c
+
 
cells.  DN DC can also respond to CCL20 (via CCR6), and CD11b
+
 DC constitutively 
respond to CCL20 and CCL9 (via CCR6 and CCR1 respectively).  Of note, Crohn’s 
disease (CD) patients express significantly higher levels of CCL19, CCL21, and CCR7 
than healthy individuals
205
, and the increase in expression correlates with higher numbers 
of mature DC
206
, implicating increased DC trafficking in the pathogenesis of IBD
205
.  
Similarly, expression of CCL20, produced by the FAE, is significantly greater in CD 
patients, compared to healthy controls and patients with UC
207
.  The ability to manipulate 
these and other trafficking signals remains a relatively under-utilized avenue of 
therapeutic intervention. 
Regarding the frequencies of each subset in tissue, Jang et al. found that in the small 
intestines, DC constitute approximately 10-15% of lamina propria leukocytes and are 
composed primarily of CD11b
+CD8α- DC with fewer CD11b-CD8α+ DC and CD11b-
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CD8α- (double negative; DN) DC208.  Within the Peyer’s patches (PP) of the small 
intestines, the three subsets are closer to each other in number although the CD8α+ and 
DN population is still the minority
124
.   
The proportions of each subset described above remain relatively unchanged throughout 
the jejunem
130
 but changes in the ileum, wherein bacterial densities increase dramatically.  
Here, CD8α+ DC are greatly reduced and the double negative population presides as the 
dominant subset of DC.  Of note, this is also the principal region of the GIT wherein DC 
extend dendrites between epithelial cells in a CX3CR1-dependent manner to directly 
sample the bacteria present within the lumen.  Despite this fact however, PP appear to be 
the predominant site of antigenic recognition and induction of tolerance or immunity by 
the adaptive immune system
209
.  In the colon, the CD11b
+
 DC is again the predominant 
subset constituting around 50% of DC, with approximately 30% DN DC, and 20% 
CD8α+ DC204.  To date, no studies have examined which DC populations exist in the 
cecum, a region of the GIT specialized for absorption of electrolytes and the digestion of 
high fiber material, containing prominent lymphoid tissue, particularly in the apical 
portion, and a specialized and distinct microbial population
210
.  Additionally, the few 
studies that have associated microbially induced inflammation with the function of 
intestinal DC subsets utilized Staphylococcus aureus, a dermal pathogen, as the 
inflammatory stimulus
124
. 
In the present study, we employed a model of inflammatory bowel disease (IBD) in 
which cecal inflammation is induced via experimental infection with the opportunistic 
pathogen H. hepaticus.  Not all mouse strains are susceptible to H. hepaticus-induced 
inflammation; while both strains are readily colonized, inbred A/JCr (A/J) mice are 
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susceptible to inflammation, while C57BL/6 (B6) serve as a resistant control.  Following 
inoculation with H. hepaticus, A/J mice experience acute fluctuations in the expression of 
several inflammatory cytokines and chemokines but histologically visible inflammation 
does not develop until ninety days post-inoculation (PI), presumably due to two factors.  
First, H. hepaticus is not an overt pathogen in that mono-association with the microbe 
does not cause disease in any strain tested, and only some strains are susceptible to H. 
hepaticus-mediated enteric inflammation.  Second, H. hepaticus has been shown to cause 
intestinal inflammation by inducing host immune responses against non-pathogenic 
commensal microbes, likely resulting from a H. hepaticus-mediated barrier defect.  Thus, 
collectively, H. hepaticus is thought to behave as a provocateur, providing an ideal model 
of IBD in which aberrant immune responses are directed against commensal microbes. 
In the cecum of naïve susceptible A/J mice, we detected significantly greater numbers of 
DC, both as a percentage of cells overall and in absolute number, relative to disease-
resistant B6 mice.  Regarding the different subsets of DC described in other regions of 
the GIT, we hypothesized that the cecum of A/J mice would harbor greater proportions of 
CD8α+, or perhaps DN DC, the populations considered to be the main sources of IL-
12/23p40.  We considered CD8α+ DC to be more likely as the DN population in the 
ileum was shown to produce primarily IL-12/23p40 in conjunction with IL-23p19
130
 
whereas the IL-12/23p40 detected in A/J mice skews the immune response toward a TH1 
profile as determined by a comprehensive cytokine pathway analysis
131
.  In naïve A/J 
mice, we detected significantly higher numbers of CD8α+ and DN DC and, surprisingly, 
also CD11b
+
 DC, shown to produce abundant IL-10 when stimulated
124, 211
.  Thus, there 
are greater numbers of all previously characterized DC subsets in the cecum of naïve A/J 
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mice.  Of note, we also identified a novel and distinct subset of DC in the cecum of both 
mouse strains expressing both CD8α and CD11b (double positive; DP DC).  These cells 
constituted between 10 and 15% of the CD11c
+
 cells and expressed both markers at 
levels equivalent to the single-positive subsets, however their numbers did not differ 
significantly between strains and the function of these cells is unclear.   
Myles et al. determined that, following inoculation with H. hepaticus, a peak in 
inflammatory cytokine transcription occurs at approximately four days (4d) PI.  The 
expression of these cytokines then either gradually wanes and increases again coincident 
with the development of inflammation, or remains elevated throughout the first 90 days 
PI
131
.  In particular, IL-12/23p40 is significantly elevated in 4d PI A/J mice relative to 
uninfected controls, and remains elevated until inflammation occurs.  Additionally, IL-12 
is causative in this model as antibody neutralization of IL-12 abrogates disease 
completely.  Thus, as DC are recognized as the primary source of IL-12, we next sought 
to determine if one subset of DC was differentially recruited to the cecum of A/J mice at 
4d PI.  Our results demonstrate that both CD8α+ and DN DC are again present in 
significantly greater numbers in the ceca of A/J mice, relative to B6 mice, at 4d PI.  There 
was however no longer a significant difference between strains in the number of the 
immunosuppressive CD11b
+
 subset.  Comparing the numbers of each subset within each 
mouse strain at the different time points, it is apparent that CD8α+ and DN DC are 
recruited to the cecum of A/J mice following infection with H. hepaticus; of note, CD8α+ 
DC are increased three-fold in 4d PI A/J mice.  Comparison of naïve and 4d PI numbers 
of each subset within each mouse strain revealed that only CD8α+ and DN DC are present 
in significantly greater numbers in A/J mice and none of the subsets is present at a 
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significantly greater frequency in B6 mice.  Overall increases of DC have been reported 
in the colon of SCID mice with adoptive transfer of CD45RB
high
 T cells
212
 or 
intraperitoneal injection of T cell blasts
125
.  Interestingly, Karlis et al. determined that 
very few of those DC expressed CD8α+ prior to disease induction, and that the number of 
that subset did not change appreciably during inflammation.  There are however many 
variables between that and the present study including mouse strain, the microbiota, and 
the presence of an adaptive immune system. 
By 90d PI, when inflammation is fully developed in A/J mice, there were no longer any 
differences between strains in the number of any DC subset.  It is noteworthy however 
that the frequency of CD11b
+
 DC had increased dramatically from the 4d PI samples in 
B6 mice, while their numbers at 4d and 90d PI were roughly equivalent in A/J mice.  
This was unexpected as Myles et al. showed that IL-10 is significantly elevated in 
infected versus uninfected A/J mice at 90d PI, and is expressed at much higher levels 
than in 90d PI B6 mice
131
.  It must be remembered however that IL-10 is also produced 
by regulatory T cells and some B cells. 
Thus, our data support the hypothesis that susceptibility to H. hepaticus-induced cecal 
inflammation in A/J mice is due, at least in part, to greater numbers of IL-12/23p40-
producing DC subsets at the site of inflammation.  Our findings also document that the 
increased presence of these inflammatory subsets exists only during the early stages of 
disease. 
While differences in the frequency of the various DC subsets may explain the disease 
susceptibility of A/J mice, there is also the possibility that the DC in A/J may have an 
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increased capacity to produce inflammatory cytokines and chemokines, when compared 
to equivalent numbers of DC from B6 mice.  To test this, we isolated all mononuclear 
cells from the cecum of naïve, 4d PI, and 90d PI A/J and B6 mice, and treated them with 
either live H. hepaticus at a density of approximately 10 cfu per cell, or E. coli LPS.  
Previous studies by MacPherson et al. showed that DC isolated from the mesenteric 
lymph nodes draining the gut are more activated and mature than DC present within the 
LP and PP of the gut
209
.  To increase the possibility that observed cytokine production 
was a result of the ex vivo stimulus, we isolated cells from the cecal LP and associated 
lymphoid follicles to obtain a greater proportion of cells that had not yet been activated.   
Bulk cells were used for two specific reasons.  Considering the rarity of DC in intestinal 
tissue of immunocompetent mice, detected at a frequency of 1.6% and approximately 2% 
in the small intestines and colon respectively
125, 212, 213
, it would require excessive 
numbers of mice to obtain adequate cell numbers for ex vivo stimulation.  Secondly, the 
inclusion of other cell types present in a physiological setting allows for a more realistic 
estimate of the capacity of DCs to produce inflammatory mediators, many of which 
depend on paracrine signals for production.  Admittedly, epithelial cells are lacking from 
the ex vivo cultures used in the present studies, the primary reason being the exclusion of 
epithelial organoids (cell aggregates) due to the necessary filtration of tissue digests in 
the isolation of cecal cells.  Additionally, anoikis, or epithelial cell necrosis in the 
absence of stromal factors, is problematic in primary cell cultures. 
It should be noted that the production of inflammatory cytokines and chemokines in H. 
hepaticus-infected A/J and B6 mice was already surveyed by Myles et al. using RT-PCR 
to analyze gene transcription
131, 182
.  There are however multiple mechanisms by which 
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the actual level of protein produced is regulated, such as RNA editing via Adenosine 
Deaminase Acting on RNA (ADAR) enzymes
214
, and miRNA which affect the stability 
of gene transcripts and thus the amount of functional protein produced
215
.  Additionally, 
Myles et al. primarily compared cytokine production between H. hepaticus-infected and 
uninfected mice of each strain at several time points rather than between mouse strains as 
in the present study.  Hence, our goal was to evaluate the capacity of cells derived from 
naïve and H. hepaticus-infected to produce functional inflammatory cytokines and 
chemokines at the protein level. 
Using cells isolated from naïve weanling mice, there was a significant difference between 
mouse strains in the production of IL-12/23p40 both at a basal level and in cells treated 
with H. hepaticus or LPS.  There was however no difference between stimulated and 
unstimulated cells in the amount of IL-12/23p40 produced.  Surprisingly, no differences 
were detected between strains in the production of any of the other 22 cytokines or 
chemokines analyzed, including IL-17, TNF-α, or IL-6.  While H. hepaticus-induced 
inflammation in A/J mice is a TH1-mediated process, we expected to see differences in 
chemokines responsible for the attraction of T cells, particularly those transcribed at 
increased levels in H. hepaticus-infected A/J mice such as CXCL10.   
This cytokine profile changed when using cells isolated from 4d PI A/J and B6 mice.  
Despite a trend toward greater IL-12/23p40 production in H. hepaticus- and LPS-treated 
cells from A/J mice when compared to cells from B6 mice, there was no significant 
difference between strains.  Additionally, the abundant IL-12 production seen in cells 
from 4d PI B6 mice is in stark contrast to previous data showing a complete lack of 
increased IL-12/23p40 transcription in H. hepaticus-infected B6 mice
131
, presumably a 
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result of the tolerizing effects of epithelial cells
200-202
 present in the experiments 
performed in live animals.  In ex vivo stimulation, epithelial cells were removed during 
the tissue digestion process and only individual mononuclear cells were plated, allowing 
for more robust inflammatory responses.  Alternatively, significantly greater production 
of TNF-α, CXCL10 (IP-10), and CCL5 (RANTES) was now detected in cultures of cells 
isolated from 4d PI A/J mice.  The increased production of TNF-α was unexpected as 
increased transcription in tissue was not noted in prior studies
131, 182
.  It is interesting 
however in light of the fact that TNF-α is elevated in both the serum216 and stool217 of 
IBD patients, likely due to a polymorphism in the TNF promoter
218
.  Additionally, 
neutralizing antibodies specific for TNF-α including infliximab, adalimumab, and 
certolizumab pegol have shown great promise in the treatment of different forms of IBD.  
The increased production of TNF-α by cells of 4d PI A/J mice underscores the utility of 
this model in the study of the human condition. 
It is worth noting that the two chemokines produced in greater amounts by cells of 4d PI 
A/J mice, CXCL10 (IP-10) and CCL5 (RANTES), are traditionally thought of as being 
produced, or induced, by cells of the adaptive immune system.  Recent work however has 
demonstrated that both of these chemokines can accumulate very rapidly due to 
activation of NK and NKT cells
219, 220
.  This is in accord with anecdotal evidence of a 
role for NK cells in H. hepaticus-mediated IFN-γ production by as early as 4 days PI131.  
While there is some evidence of a role for NK and NKT cells in the pathogenesis of 
IBD
221, 222
, their contribution to H. hepaticus-induced inflammation is unknown.  The 
CXCL10/CXCR3 axis has previously been implicated in H. hepaticus-mediated 
inflammation in A/J mice, as well as other models of IBD
223
 and the human condition
224
.  
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Interestingly, TNF-α is a potent inducer of CXCL10, providing additional evidence that 
this pathway is involved in this model of IBD and a potential avenue for therapeutic 
exploitation in humans. 
Using cells isolated from 90d PI mice, a pattern similar to that of 4d PI mice was 
observed; there was again no difference in the production of IL-12/23p40 while cell 
cultures derived from A/J mice contained significantly more TNF-α and CCL5.  As in the 
experiments using 4d PI mice, there was no significant difference between stimulated and 
untreated cells, indicating that while cells from H. hepaticus-infected mice have an 
increased capacity for production of these inflammatory mediators, it is not directly 
associated with stimulation by H. hepaticus or E. coli LPS.   
Surprisingly, we found that cells isolated from 90d PI B6 mice produced greater amounts 
of IL-6 and the chemokines CXCL1 (KC) and CCL2 (MCP-1).  IL-6 is an innate 
inflammatory cytokine typically produced in concert with TNF-α, making its relatively 
greater production in cells from B6 mice that much more unexpected.  While IL-6 is 
traditionally considered pro-inflammatory, there are reports that in some instances it 
exerts anti-inflammatory effects due to an ability to induce circulating IL-1 receptor 
antagonist and soluble TNF receptor p55
225
.  Additionally, IL-6 and TGF-β function 
synergistically to induce the differentiation of TH17 cells, which may, in turn, inhibit TH1 
development via down-regulation of IL-12Rβ2226.  It is also noteworthy that the 
chemokines produced at greater levels in B6 cultures, CXCL1 and CCL2, are 
chemotactic for neutrophils and monocytes respectively, whereas those chemokines 
found in greater amounts in A/J cultures, CXCL10 and CCL5, are primarily chemotactic 
for T cells.  Thus, those chemokines the production of which is favored in A/J mice are 
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more logical factors in mediating the lymphocytic infiltration seen histologically in this 
model of IBD and in clinical IBD. 
Surprisingly, IL-10 was undetectable at any time point in either strain, in contrast to 
Myles’ data.  This, and other data discordant with earlier studies of in gene transcription 
in tissue, are presumably due to differences in the experimental design, as well as 
differences in the method of cytokine quantitation.   
Collectively, our data support the hypotheses that there are differences between A/J and 
B6 mice in both the number of inflammatory DC subsets and their capacity for the 
production of specific inflammatory mediators including IL-12/23p40, TNF-α, CXCL10, 
and CCL5. 
Development of A/JCr.129- Batf3
tm1Kmm
 mice 
While the above data correlate nicely with the observed disease susceptibility of A/J 
mice, the true physiological significance of CD8α+ DC will need to be verified using an 
in vivo model.  With that aim in mind, we developed the congenic the A/JCr.129-
Batf3
tm1Kmm
 mouse strain lacking CD8α+ DC.  The original knock-out mouse on a 
129/SvEv background lacked only the CD8α+ DC subset and retained all other DC 
subsets and leukocytes examined.  The congenic strain on an A/J background is similar in 
phenotype and we hypothesize that disease will subsequently be reduced or greatly 
abrogated.  Studies are ongoing to confirm the in vivo relevance of these cells to chronic 
enteric inflammatory disease. 
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CHAPTER 3 
OVERVIEW 
Colorectal cancer (CRC) is the second leading cause of cancer mortality in the U.S., and 
the third most common type of cancer in men and women
227
.  Along with certain 
hereditary conditions, Inflammatory Bowel Disease (IBD) ranks as one of the top three 
high-risk conditions for CRC
141
.  For IBD-associated CRC, there is no well-defined 
genetic etiology and CRC is thought to develop from a hyperplastic or dysplastic 
precursor lesion as a sequela to chronic inflammation.  Classically, the stage of disease at 
diagnosis, as established by Dukes in 1932
228
, provides a prognostic indicator of 
survival
229
 as resection prior to lymph node metastasis is often curative.  Alternatively, 
diagnosis of CRC at Dukes’ stage C or higher, indicating lymph node metastasis, is 
associated with poor five year survival rates, demonstrating the necessity of early 
detection.  Currently, the most commonly utilized screening techniques are fecal occult 
blood testing (FOBT), sigmoidoscopy, colonoscopy, and CT colonography (often called 
virtual colonoscopy), all of which possess both advantages and disadvantages.  FOBT is 
affordable and non-invasive but fails to detect most early pre-cancerous polyps and some 
cancerous lesions in humans
230, 231
.  The endoscopic techniques can be used to biopsy or 
completely remove potential lesions at the time of the procedure however they require 
cleansing of the colon, sedation in the case of colonoscopy, and there is an inherent risk, 
albeit minimal, of damage to the mucosa.  Additionally, sigmoidoscopy is unable to 
detect lesions in the proximal colon
232
.  CT colonography also requires cleansing of the 
colon.  Mouse models of CRC are posed with similar challenges, particularly in the 
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setting of therapeutic studies.  As in humans, FOBT testing is limited by the same lack of 
robust sensitivity and specificity, and while colonoscopy is possible in mice
233, 234
, it is 
both time- and cost-intensive, and requires anesthesia and substantial expertise.  
Helicobacter-infected Smad3-knockout mice represent an attractive animal model for the 
study of CRC.  Mice deficient in Smad3, a transcription factor downstream of the anti-
inflammatory and pro-apoptotic cytokine TGF-β, develop only a few mild phenotypic 
abnormalities including megaesophagus, an increased incidence of teratomas, and, at a 
very low incidence, angular limb deformities
235
 when raised in specific pathogen-free 
(SPF) conditions.  However, when infected with enterohepatic species of Helicobacter, 
e.g. H. bilis or H. hepaticus
156
, approximately two thirds of these mice develop mucinous 
adenocarcinoma (MUC) of the proximal colon by as early as 6 weeks post-infection (PI).  
H. bilis and H. hepaticus induce intestinal inflammation in susceptible strains of mice
182, 
236
 and the neoplasia seen in Helicobacter-infected Smad3
-/- 
mice is considered a post-
inflammatory phenomenon
156
.  Additionally, loss of normal TGF-β signaling is widely 
recognized as an indicator of malignancy in human CRC
237, 238
.  Thus, the targeted 
deletion of Smad3 in mice is a biologically relevant model of the human condition. 
This model is ideal for therapeutic studies of CRC in that the majority of mice develop 
disease on a predicted time course.  Moreover, cancer develops in its natural setting as 
opposed to the more commonly used models that employ flank injections of 
immunocompromised mice with human cancer cell lines.  To enhance the usefulness of 
this model, it would be ideal to be able to identify CRC at early stages of disease or even 
prior to disease onset.  This would allow for both the elimination of mice from expensive 
therapeutic studies as well as the assessment of therapeutics at various stages of disease.  
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For the purposes of evaluating therapeutic compounds for the treatment of CRC, we 
endeavored to establish a method of screening H. bilis-infected Smad3
-/-
 mice prior to the 
time at which disease typically occurs.  Our goal was to refine this mouse model of CRC 
in an effort to reduce animal numbers and the associated costs, and to increase the power 
of the data generated in these trials.  Toward these ends, we evaluated both magnetic 
resonance imaging (MRI) and several fecal RNA biomarkers as means of detecting 
disease and predicting disease severity in H. bilis- and sham-inoculated Smad3
-/-
 mice in 
two separate, sequential longitudinal studies using different cohorts of mice.  MRI was 
selected, as opposed to CT, based on the greater soft tissue definition afforded by this 
modality.  Non-contrast enhanced MRI was able to detect MUC lesions beginning at 8 
weeks PI and 58% of mice with histologically confirmed lesions were correctly identified 
at 16 weeks PI.  However, serial imagings produced inconsistent results.  Additionally, 
MRI requires considerable resources to perform, and image interpretation is inherently 
subjective and requires expertise.  Alternatively, fecal expression of mRNA specific for 
IL-1β, MIP-1α, and RANTES at 3 weeks PI correlated significantly with MUC lesion 
severity at 9 weeks PI in H. bilis-infected Smad3
-/-
 mice, allowing the identification of 
which mice have a high probability of developing MUC.   
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MATERIALS & METHODS 
Bacteria and Cultivation.  A Helicobacter bilis isolate was obtained from an 
endemically infected mouse colony using a previously described culture technique
186
.  
The isolate was identified as H. bilis based on ultrastructural morphology, biochemical 
characteristics, and sequence analysis of the 16s rRNA gene
187
.  For inoculation, H. bilis 
cultures were grown in 5 mL of Brucella broth (Becton Dickinson, Franklin Lakes, NJ) 
supplemented with 5% fetal calf serum (Sigma-Aldrich Co., St. Louis, MO) and overlaid 
on blood agar plates and incubated for 24 to 48 hours at 37 °C in a microaerobic 
environment containing 90% N2, 5% H2, and 5% CO2. 
Animals.  All studies were performed in accordance with the Guide for the Care and Use 
of Laboratory Animals and were approved by the University of Missouri Institutional 
Animal Care and Use Committee.  129-Smad3
tm/Par
/J (referred to as Smad3
-/-
) mice were 
bred on-site for these studies.   Mice were confirmed to be free of adventitious viruses, 
parasites, and pathogenic enteric and respiratory bacteria, including all known murine 
Helicobacter spp.  Three to four week old Smad3
-/-
 mice were inoculated twice, 24 hours 
apart, with 10
8
 H. bilis organisms in 0.5 mL Brucella broth, or an equivalent volume of 
sterile broth, via gastric gavage.  Separate cohorts of mice were used for each study 
including weight of mice (n = 9 to 14; figure 3.1), incidence of CRC (n = 5 to 9 mice per 
time point; figures 3.3), MRI (n = 6 of each sex infected with H. bilis, and 1 of each sex 
sham-infected; figure 3.4), 2 to 9 week PI fecal 18s rRNA gene copies (n = 7 H. bilis-
infected and 9 sham-infected; figure 3.5),  9 week PI fecal mRNA levels (n = 7 H. bilis-
infected and 9 sham-infected; figure 3.6), 1 to 7 week PI fecal mRNA levels (n = 14 H. 
bilis-infected and 9 sham-infected; figure 3.7), and Spearman’s rank order correlation and 
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receiver operating characteristic curves (n = 14 H. bilis-infected mice; figures 3.8 and 
3.9).  Mice were group-housed according to infection status in autoclaved microisolator 
cages and were provided autoclaved food and water.  All manipulations and sample 
collections were performed in a biosafety hood except for MRI.  Mice were euthanized at 
16 or 9 weeks PI for the MRI and fecal biomarker studies respectively, via inhaled 
overdose of CO2. 
Magnetic Resonance Imaging.  MRI was performed at 3, 5, 8, 10, 12, 14, and 16 weeks 
PI using a 7T/210mm Varian Unity Inova MRI system equipped with a quadrature driven 
birdcage coil (38mm I.D.) (Varian Inc., Palo Alto, CA). Mice were anesthetized with 1–
2% isoflurane in oxygen via a nose cone. A respiratory sensor was placed on the 
abdomen for monitoring of vital signs; body temperature was supported with warm air 
circulating in the magnet bore (SA Instruments Inc., Stony Brook, NY). Coronal and 
axial planes were collected using a spin echo T1-weighted imaging sequence with a fat-
saturation pulse applied to suppress the strong signals from fatty tissues. Typically, 
images were collected with 21 slices, 0.8 mm slice thickness, pixel resolution of 59 mm x 
127 mm (coronal planes) and 59 mm x 59 mm (axial planes), and 4 scans to average 
the motion artifacts. Images were processed using VnmrJ (Varian Inc., CA). 
Sample Collection and Experimental Design.  For collection of fecal samples, mice 
were individually placed in autoclaved cages containing no bedding within a biosafety 
hood.  Fecal pellets were collected at 1, 3, 5, 7, and 9 weeks PI with a sterile tuberculin 
syringe and placed in 200 µL RNAlater® (Ambion, Austin, TX) for isolation of RNA.  
Pellets in RNAlater® were homogenized with a TissueLyser (Qiagen Inc., Valencia, 
CA), centrifuged briefly (Marathon 16km, Fisher Scientific, Pittsburgh, PA), and then 
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vortexed to resuspend fecal material.  Following euthanasia, the intestinal tract from 
ileum to rectum was collected and fixed in formalin.   
Histopathology and Ranking of Lesions.  Formalin-fixed tissues from H. bilis- and 
sham-infected mice were embedded in paraffin, cut in 5 µm-thick sections, and processed 
for staining with hematoxylin and eosin.  CRC lesions in H. bilis-infected mice were 
ranked in a blinded fashion by two laboratory animal pathologists (AE and CF) according 
to lesion severity, based on the number of lesions, the longitudinal and vertical extent of 
neoplastic lesions, and the degree of associated inflammation.  Rankings were compared 
and, in the case of discrepancies in ranking, pathologists conferred and agreed upon a 
rank order. 
RNA Extraction from Feces.  Total RNA was extracted using the RNeasy Mini Kit 
respectively, according to the manufacturer’s protocols (Qiagen).  RNA was quantified 
using a Nanodrop-1000 spectrophotometer (Nanodrop, Wilmington, DE) and quality was 
assessed by measuring the absorbance at 260 and 280 nm. 
Reverse Transcription.  Five micrograms of total RNA were reverse transcribed using 
reverse transcriptase and oligo(dT) primers according to the manufacturer’s protocol 
(SuperScript® First-Strand, Invitrogen, Carlsbad, CA).  cDNA was diluted 1:1 with 
DPEC-treated water. 
Semiquantitative Real-time Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR).  Semiquantitative real-time RT-PCR was used to measure mRNA levels in feces 
(LightCycler 1.5, Roche Diagnostic, Nutley, NJ).  PCR reactions and melting curves 
were performed in a 20 µL volume in glass capillaries containing 0.5 µM of each primer, 
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3 mM MgCl2, QuantiTect SYBR Green PCR Master Mix (Qiagen), and cDNA.  To 
quantify the number of copies of specific cDNA, a standard curve was created using 
known concentrations (10
1
 to 10
6
 copies) of the pCR4-TOPO (Invitrogen) plasmid 
containing the transcript of interest.  PCR reactions were incubated at 95 °C for 15 
minutes to activate the polymerase followed by 40 cycles consisting of a 15-second 
denaturing at 94 °C, 20-second annealing (see Table 1 for primer specific annealing 
temperature), and a 30-second extension at 72 °C.  The ramp rate was 3 °C/s for 
annealing and 20 °C/s for all other steps.  Fluorescence was monitored at the end of each 
extension phase.  Following amplification, melting curves were generated to confirm 
PCR product identity.  
Primer Sequences and Plasmids.  The sequences for HPRT
239
, 18s rRNA
131
, IL-1β240, 
MCP-2
241
, and MIP-1α131, have been previously reported in the literature.  The primer 
sequence for RANTES was designed from published mRNA sequences using DS Gene 
software (Accelrys, San Diego, CA).  Primer sequences are listed in Table 1.  Standards 
were generated using linearized plasmids containing cloned amplicons of selected targets 
using the Topo TA PCR-cloning kit (Invitrogen, Carlsbad, CA).  Transcripts were 
quantified by comparing fluorescence of experimental samples to that of plasmid 
standards containing known concentrations of the cloned product. 
STATISTICAL ANALYSES 
Semiquantitative real-time RT-PCR.   Semiquantitative real-time RT-PCR was used to 
measure mRNA levels in feces.  The expression of IL-1β, MIP-1α, MCP-2, and RANTES 
were normalized to expression of the house-keeping gene HPRT.  The significance of 
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differences in normalized expression levels between H. bilis-infected (n = 7) and sham-
infected (n = 9) Smad3
-/-
 mice at 9 weeks PI was determined using the Mann-Whitney 
Rank Sum Test.  The significance of differences between H. bilis-infected MUC+ (n = 
11), H. bilis-infected MUC- (n = 3), and sham-infected mice (n = 9) at 1 to 7 weeks PI 
was determined using the Kruskal-Wallis one way ANOVA on Ranks and Dunn’s 
method of multiple pairwise comparisons. 
Correlation to Lesion Ranks.  Coli were evaluated histologically and ranked according 
to lesion severity.Rank order of lesion severity in H. bilis-infected Smad3
-/-
 mice was 
correlated to the rank order of normalized expression of each biomarker using Spearman 
Rank Order Correlation (SROC).   
Receiver-operator Characteristic (ROC) Curves.  Based on the presence or absence of 
CRC on histological interpretation, ROC curves were generated from H. bilis-infected (n 
= 14) Smad3
-/-
 mice using the statistical software package SigmaPlot (SPSS, Chicago, 
IL).  R software
242
 was used to compute the confidence intervals for the area under the 
curve (AUC) based on DeLong’s method243 as well as to compare ROC curves to each 
other based on the Hanley and McNeil method
244
.  For confidence intervals for the AUC, 
upper limits were truncated at unity.  
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RESULTS 
Progression of colon cancer in Smad3
-/-
 mice.  Smad3
-/-
 mice on a 129/Sv background 
develop colonic neoplasia but this phenotype is dependent upon infection with either H. 
bilis or H. hepaticus, with tumors developing most often in the proximal colon
155, 156
.  
Clinically, mice appeared completely normal and show no external evidence of disease 
such as hunched posture, scruffy haircoat, lethargy, or abnormal stool.  Mice were also 
apparently eating and drinking normally as individuals infected with H. bilis gained 
weight at the same rate as sham-inoculated control mice (figure 3.1).  In the present 
study, the tumors were typically single masses although less than 10% developed a 
second mass at other sites in the colon.  Grossly, tumors appeared as either a thickened, 
pale area of the proximal colon, or as pearlescent, lobulated, exophytic masses reflecting 
the abundant mucin production seen in most masses (figure 3.2A).  Histologically, these 
tumors were best classified as MUC, with an appearance similar to that seen in humans.  
Tumors were characterized by marked goblet and epithelial cell hyperplasia with 
extensive production of mucus, often seen sequestered in large dilated “mucin lakes”, 
spilling into the lumen of the GI tract or penetrating the serosal surface and spilling into 
the peritoneal space (figure 3.2B-D).  In the latter case, peritonitis was not uncommon.  
Many of the neoplastic epithelial cells retained a simple tall columnar morphology with 
centrally located, oblong nuclei containing a vesicular chromatin pattern.  There were 
also abundant goblet cells, often approaching a 1:1 ratio with columnar epithelial cells.  
Surrounding the accumulations of mucinous material, the epithelium was variably 
attenuated, and sloughed epithelial and inflammatory cells were seen in the mucinous 
material, which was characterized by a lightly basophilic, homogenous to lacy 
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appearance.  There were also mild to moderate mixed inflammatory infiltrates in the 
areas around the tumor.  Mitotic figures ranged from 0 to 4, with an average of 1 per HPF 
(400×).  In the absence of Helicobacter infection, Smad3
-/-
 mice did not develop MUC or 
any detectable intestinal inflammation.   
Incidence of MUC in Smad3
-/-
 mice.  To determine if the incidence of MUC would 
increase with increasing duration of infection, Smad3
-/-
 mice orally infected with H. bilis 
were sacrificed at multiple time points post-infection and the GI tract was collected for 
histological examination.  Tissues were nominally classified as being neoplastic 
(possessing a characteristic MUC lesion), hyperplastic (showing evidence of focal or 
diffuse epithelial hyperplasia but not neoplasia), or lesion-free.  While 100% of mice 
(5/5) examined at 9 weeks PI had developed characteristic MUC lesions, only 40% of 
mice (2/5) at 11 weeks PI and 88% of mice (7/8) at 13 weeks PI showed histological 
evidence of neoplasia (figure 3.3).  This was not a function of the early time point as 
similar results were obtained with mice at 20 weeks PI (data not shown).  Thus, while the 
majority of mice developed identifiable MUC by as early as 6 weeks PI, not all mice 
progressed to MUC regardless of the duration of infection.   
MRI detection of MUC in Smad3
-/-
 mice.  H. bilis-infected Smad3
-/-
 mice (n = 12, 6 
male and 6 female) and naïve wild-type mice of the same background strain (1 male, 1 
female) were imaged using MRI without contrast at 3, 5, 8, 10, 12, 14, and 16 weeks PI.  
Both coronal and axial images were collected at 0.8 mm intervals resulting in a total of 
approximately 14 and 18 images respectively needed to completely visualize the 
abdominal contents of one mouse.  Immediately after the final imaging, mice were 
euthanized, and carefully dissected and photographed without disturbing the position and 
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orientation of abdominal contents in situ.  Gross findings were then compared to the 16 
week PI images to assess the capacity of MRI to detect intestinal lesions and evaluate the 
level of background signal in control mice.  Additionally, images from earlier imaging 
sessions were reviewed to determine if lesions at necropsy could be detected 
retrospectively.  The earliest time point at which Helicobacter-infected mice were 
interpreted as possessing a neoplastic lesion was 8 weeks PI.  While we were able to 
identify a reasonable agreement between the final (16 week PI) images and gross 
necropsy findings in 7 of 12 H. bilis-infected mice (sensitivity = 58.33%) (figure 3.4), 5 
of 12 mice with histologically identifiable MUC were interpreted as MUC-negative at 16 
weeks PI.   
Total fecal DNA and 18s rRNA as a biomarker of MUC at 9 weeks PI in H. bilis-
infected Smad3
-/-
 mice.  To determine if the incidence of MUC could be detected via 
DNA or RNA-based fecal biomarkers, total DNA was isolated from H. bilis-infected and 
sham-inoculated mice.  DNA was present in significantly greater quantities in the feces of 
H. bilis-infected mice, however the amount of fecal DNA isolated at any time point post-
inoculation failed to correlate with lesion severity at necropsy.  As DNA isolated from 
feces may be of host or microbial origin, we also wanted to determine whether the 
amount of host DNA shed in the feces, reflecting the rate of intestinal epithelial 
sloughing, provided useful information regarding the presence or severity of MUC.  The 
number of copies of the eukaryotic 18s rRNA gene was thus assessed via real-time PCR 
and normalized to the amount of overall DNA isolated.  Again, the normalized number of 
18s rRNA gene copies present in the feces differed significantly between H. bilis-infected 
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and sham-inoculated mice (figure 3.5) however no correlation between lesion severity 
and gene copy number at any time point was detected. 
Fecal cytokine gene expression as a biomarker of MUC at 9 weeks PI in H. bilis-
infected Smad3
-/-
 mice.  At 9 weeks PI, H. bilis-infected Smad3
-/-
 mice expressed 
significantly higher levels of IL-1β (p = 0.001, Mann-Whitney Rank Sum test), MIP-1α 
(p = 0.004), and RANTES (p = 0.003) (figures 3.6A-C) than sham-inoculated mice.  
However, no difference was detected in the expression of MCP-2 despite a trend toward 
elevated expression in H. bilis-infected mice (figure 3.6D).  Two sham-inoculated mice 
expressed levels of MCP-2 comparable to even the highest expressing H. bilis-infected 
mice, thus MCP-2 was eliminated from further experiments.  In this cohort of mice, all 7 
Helicobacter-infected mice developed histologically identifiable MUC.  Spearman’s 
Rank Order Correlation (SROC) was then performed in order to correlate the expression 
of IL-1β, MIP-1α, and RANTES with lesion severity in the H. bilis-infected mice.  
Correlation coefficients for IL-1β, MIP-1α, and RANTES were 0.929 (p < 0.001), 0.536 
(p = 0.18), and 0.750 (p = 0.04) respectively, indicating significant correlation between 
lesion scores and expression of both IL-1β and RANTES.  Based on the significant 
overall difference in expression between infected and control mice in MIP-1α expression, 
along with the fact that the two mice with the lowest MIP-1α mRNA levels also 
demonstrated the lowest lesion scores, we opted to retain MIP-1α in subsequent studies.  
Additionally, the kinetics of chemokine and cytokine expression vary, and we reasoned 
that at earlier time points, MIP-1α might still prove to be a useful biomarker, despite poor 
overall correlation at 9 weeks PI. 
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Fecal cytokine gene expression during the progression of MUC in H. bilis-infected 
Smad3
-/-
 mice.  To determine if fecal mRNA levels of IL-1β, MIP-1α, and RANTES at 
time points earlier than 9 weeks PI could predict subsequent disease occurrence or 
severity, mice were inoculated as before with H. bilis (n = 14) or sterile broth (n = 9) and 
fecal samples were collected every two weeks starting at 1 week PI and continuing until 7 
weeks PI.  Mice were euthanized at 9 weeks PI and tissues were collected for histological 
examination.  The normalized expression of each biomarker was determined at each time 
point, revealing similar kinetics for all three biomarkers (figure 3.7).  Expression of all 
three biomarkers peaked at 1 week PI and then steadily declined thereafter in 
Helicobacter-infected mice.  Nonetheless, even at 7 weeks PI, there was a significant 
difference (Mann-Whitney Rank Sum Test, p < 0.05) between H. bilis-infected MUC
+
 
and sham-infected mice for all three biomarkers.   
To assess the value of each biomarker and determine the optimal screening paradigm, 
expression at each time point was correlated to lesion rank at 9 weeks PI using SROC.  
Additionally, receiver-operator characteristic (ROC) curves were generated to establish 
sensitivity, specificity, and appropriate cut-off values for each biomarker.  SROC analysis 
of samples from 1 to 7 weeks PI revealed a significant correlation (p < 0.05) between 
lesion severity at 9 weeks PI and expression of IL-1β at 1, 3, and 5 weeks PI, MIP-1α at 3 
and 5 weeks PI, and RANTES at 3 weeks PI, indicating 3 weeks PI may be the optimal 
time for testing mice (figure 3.8).  Surprisingly, the correlation between lesion rank and 
the expression of all three biomarkers was not statistically significant at 7 weeks PI.  
However, SROC indicates the overall agreement between lesions and the selected 
biomarkers across the entire range of lesion severity.  As our goal was to identify “poor 
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responders” and eliminate mice at the low end of the disease spectrum, ROC curves at 
each time point were compared to determine if very high specificity (>0.98) and 
acceptable sensitivity (>0.80) could be achieved simultaneously.  Considering the poor 
correlation for all markers at 7 weeks PI, empirical ROC curves were produced for only 
1, 3, and 5 weeks PI (figure 3.9).  Confidence intervals were established using DeLong’s 
method
245
 and the upper limit was truncated at one, as area under the curve (AUC) 
values, by definition, cannot exceed unity.  All three biomarkers examined provided an 
estimated AUC of 0.97 at 3 weeks PI (figure 3.9D-F; 95% CI = 0.89 to 1).  At 5 weeks 
PI however, fecal mRNA levels of IL-1β yielded an estimated AUC of 1, thus providing, 
in this sample, perfect sensitivity and specificity in predicting the presence or absence of 
MUC in mice at 9 weeks PI (figure 3.9G).  However, ranking the relative performance of 
IL-1β at 5 weeks PI and IL-1β, MIP-1α, or RANTES at 3 weeks PI is difficult because 
the small sample size gives limited power to discern differences in AUC; not 
surprisingly, none of the markers shown in figure 3.9 were statistically different from 
each other (smallest p-value = 0.1), using the method of Hanley and McNeil
246
.  As the 
goal of this study was to establish a screening method with the ability to predict which 
mice would not develop CRC as a means of conserving resources, it should be noted that 
by as early as 1 week PI, IL-1β provided an AUC of 0.97 (95% CI = 0.89 to 1), the same 
as all three biomarkers at 3 weeks PI.  Additionally, the overall correlation between 
lesion severity rank at 9 weeks PI and fecal mRNA levels of IL-1β at 1 week PI was 0.65 
(p = 0.01; Spearman rank order correlation).  Thus we propose that in this model of 
MUC, RT-PCR analysis of fecal mRNA specific for IL-1β at 1 week PI, or of IL-1β, 
MIP-1α, or RANTES at 3 weeks PI is a reliable, non-invasive determinant of which mice 
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will not progress to MUC.  More importantly, this provides proof-of-principle that fecal 
nucleic acid analysis has utility in mouse models of gastrointestinal neoplasia, as a means 
of reducing the number of animals used in study.  This may also portend novel screening 
methods of interest to the human population. 
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DISCUSSION 
The World Health Organization defines MUC in humans as a tumor with >50% showing 
a mucinous pattern on histological examination, and with a large amount of extracellular 
mucin produced by secreting acini
247
.   Of colorectal cancer, MUC account for between 
11 and 15%
248
.  Helicobacter-infected Smad3
-/-
 mice recapitulate the human condition 
faithfully, with extensive mucin production seen multifocally in neoplastic foci, forming 
dilated pockets of mucinous material extending into the lumen and frequently through the 
tunica muscularis to the serosal surface of the GI tract.   There are several reasons to 
believe that the mechanisms leading to MUC in humans and Helicobacter-infected 
Smad3
-/-
 mice are similar.  In humans, as in Helicobacter-infected Smad3
-/-
 mice, MUC 
occurs more frequently in the proximal colon than elsewhere in the GI tract
249-251
.  While 
not all studies agree, possibly due to geographical differences
252
 or the presence of two 
subtypes of colorectal MUC
249
, MUC in humans appears to be more prevalent as a 
sequela to IBD than as spontaneous CRC not associated with prior IBD
142, 251, 253-255
.  
Supporting this concept, MUC occurs primarily in areas of chronic inflammation and the 
risk of MUC increases with duration of IBD
256, 257
.  Similarly, the findings detailed herein 
support the notion that the severity of MUC in Helicobacter-infected Smad3
-/-
 mice is 
largely dependent on the robustness of the inflammatory response to a member of the gut 
flora, as measured by the expression of certain fecal cytokines and chemokines.  
Additionally, MUC in humans is frequently associated with fistula formation
251, 254, 258-261
, 
a phenomenon attributed to adenomatous transformation of the epithelium lining the 
fistula tract
262
.  Many H. bilis-infected Smad3
-/-
 mice showed histologic evidence of 
perforation of the bowel wall and areas in which dysplastic epithelial cells are seen 
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invading and penetrating the serosal surface (Figures 1B-D), and it is tempting to 
speculate that a similar mechanism is at work in the formation of MUC lesions in Smad3
-
/-
 mice.   
Regardless of the pathogenesis, not all Smad3
-/-
 mice will develop MUC despite 
persistent colonization with H. bilis.  As a consequence, many of these MUC-resistant 
mice will be utilized in expensive therapeutic trials lasting up to 8 months in duration.  
Along with the time and money spent maintaining mice that will not progress to MUC, 
one must also consider that these mice are potentially confounding the research by 
making therapeutic compounds appear falsely efficacious.  The ability to non-invasively 
identify which mice will not progress to cancer would both conserve resources and 
increase the power of data generated by using only mice with a high probability of 
developing MUC.  We first evaluated MRI as a means of detecting early inflammatory or 
precancerous lesions in Helicobacter-infected Smad3
-/-
 mice.  Mice were imaged every 
two to three weeks until 16 weeks PI, a time by which previous studies (Figure 2) had 
demonstrated the majority of mice would develop MUC.  While MRI provided some 
diagnostic information, i.e. the presence or absence of a lesion, it afforded little 
prognostic information regarding the severity or extent of disease at necropsy when 
images were analyzed retrospectively.  This is partially due to the variability between 
images from week to week.  Frequently, MRI would indicate a possible lesion at one time 
point, followed by images at subsequent time points interpreted as negative.  In only one 
of twelve mice did images consistently contain suspect lesions following the initial 
appearance.  Additionally, in those mice in which a correlation between 16 week PI MRI 
images and gross lesions was detected, it was difficult to reliably track the course of 
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intestinal neoplasms retrospectively.  The background noise, seen in both experimental 
and control mice, was considerable and was most problematic in highly glandular tissue 
such as the reproductive tract.  Additionally, the severity of the lesions could not be 
predicted based on the size and intensity of suspect lesions on MRI.  Mice with 
hyperintense signal on the final imaging, indicating a large or severe lesion, often 
revealed mild or moderate MUC lesions at necropsy.  Conversely, mice with borderline 
‘positive’ final images often revealed extensive marked MUC or even multiple lesions.  
MRI has been applied to the human population as a screening method for MUC; 
however, the method requires insufflation of the colon with air to enhance imaging
227
.  
The lack of insufflation in our study may partially explain the lack of adequate definition 
with MRI.  Also, the imaging in this study was performed without the use of contrast.  
MRI studies of the gastrointestinal tract using a fecal-tagging based MRI contrast agent 
may enhance visualization of MUC lesions
263
.  The primary goal of these studies was to 
evaluate two distinct methods of detecting CRC in a mouse model, non-invasively and as 
early in the disease process as possible.  As our motivation was to conserve resources, we 
opted to omit insufflation and contrast in an effort to keep the procedure as simple and 
cost-effective as possible.  In our study, a mass showing hyperintense and heterogeneous 
signal contents would indicate a MUC lesion (Figure 3B and 3C).  However, abdominal 
motion artifacts and significant signals from feces often cause ambiguities or missed 
detections.  A respiratory-gated T2-weighted MRI protocol may be applied to increase the 
detection accuracy and specificity for MUC, due to the brighter signal nature of mucin 
contents in MUC lesions on T2-weighted images; however with the expense of prolonged 
imaging time.  Lastly, considering the expense of the initial purchase, maintenance, and 
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operation, MRI is a costly technique for screening large numbers of animals.  Imaging in 
both coronal and axial planes resulted in 21 and 42 images respectively per mouse at each 
time point which, along with the user-dependent nature of image interpretation, made this 
a time-consuming and subjective technique.  As our impetus for screening animals is to 
eliminate mice that are not going to develop MUC as a means of saving costs, MRI is 
problematic.  Thus, the inability of MRI to detect disease in a reproducible manner, the 
associated costs, and the labor-intensive and subjective nature of this method, make it 
less than ideal for our purposes. 
Next, we elected to determine if CRC in our model could be predicted through the 
analysis of fecal cytokine and chemokine message levels.  This concept, while not new in 
humans
264, 265, has not been applied to murine models to the authors’ knowledge.  As 
humans and mice both constitutively slough colonic epithelial cells in feces, the RNA 
isolated from these cells should reflect the state of health or inflammation present in the 
gut.  Inflammation is now recognized as a risk factor and negative prognostic indicator 
for certain types of neoplasia in humans
266
.  Adaptive antitumoral immune responses, 
particularly those mediated by CD8
+
 T cells, are considered protective and beneficial in 
destroying tumor cells, while inflammation due to innate immune responses is often 
associated with a poor prognosis
267
.  This concept can be extrapolated to the chemokines 
responsible for attracting T cells or macrophages; accumulation of lymphocytes due to 
increased expression of CXCL16 correlates with a favorable outcome in human CRC
268
, 
while accumulation of tumor-associated macrophages due to increased levels of CCL2 
correlates with poor outcome
269
.  Thus, as a means of non-invasively assessing the degree 
of colonic inflammation in Smad3
-/-
 mice, we measured the fecal levels of several factors 
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involved in macrophage recruitment, and which have been shown to be elevated in 
human CRC
267, 270, 271
, including the chemokines MIP-1α, RANTES, and MCP-2, and IL-
1β, a highly pleiotropic pro-inflammatory cytokine with effects on virtually all cell 
types
272
.  Our initial fecal biomarker study was performed at 9 weeks PI, when the 
majority of mice were expected to have developed MUC.  It was established that a 
significant difference in the fecal expression of IL-1β, MIP-1α, and RANTES existed 
between Helicobacter- and sham-infected mice (Figure 4), however 100% (7/7) of the 
infected mice in this group developed MUC, making a comparison of MUC+ and MUC- 
mice within the infected group impossible.  Pursuing earlier time points PI (Figure 5) 
with a second group of mice provided evidence that there is also a significant difference 
in expression of these biomarkers between H. bilis-infected MUC+ and MUC- mice, 
supporting their use as predictors of MUC in this model.  It is notable that the expression 
of IL-1β, MIP-1α, and RANTES showed an acute increase following infection with 
Helicobacter, which waned steadily thereafter.  While these biomarkers are primarily 
associated with innate immune responses, infection with H. bilis eventually induces an 
adaptive immune response
80
, allowing the innate response to wane accordingly.  Like the 
selected chemokines, IL-1β is produced by the intestinal epithelium.  As intestinal 
epithelial cells also express the activating receptor IL-1RI
272
, IL-1β functions in an 
autocrine and paracrine manner to amplify chemokine expression.  Similarly, RANTES 
has been shown to stimulate production of MIP-1α by human monocytes273, suggesting 
activation of tumor-associated macrophages may amplify recruitment of additional 
monocytes and other leukocytes, thought to be the source of harmful reactive oxidative 
intermediaries.  Interestingly, several studies indicate that IL-1β may have a more direct 
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role in colorectal tumorigenesis.  In 2003, Liu et al. demonstrated that IL-1β upregulates 
the expression of cyclooxygenase (COX)-2
274
, which is over-expressed in 80-90% of 
human CRC
275
, and was also found to be elevated in Helicobacter-infected Smad3
-/-
 mice 
relative to naïve mice
156
.  Similarly, Maihöfner et al. showed that in both human CRC-
associated neoplastic epithelium and tumor-associated macrophages, COX-2 expression 
was markedly increased and that increase correlated with increases in IL-1β276.  COX-2 
functions to facilitate tumor development through the induction of anti-apoptotic and 
angiogenic factors
277, 278
, and it is worth noting that fecal mRNA levels of COX-2 have 
been evaluated as screening techniques for human CRC
279, 280
.  Additionally, IL-1β has a 
potent proliferative effect on human carcinoma cell lines
281
, most likely via the induction 
of other growth factors.  With regard to the mucinous phenotype seen in Helicobacter-
infected Smad3
-/-
 mice, IL-1β has been shown to upregulate the expression and release of 
mucins in both colonic epithelial cell lines
282, 283
 and perfused rat colon
284
.  Regardless of 
the mechanism, the present data suggest that MUC in Smad3
-/-
 mice is highly correlated 
with the prior expression of IL-1β, MIP-1α, and RANTES.   
Until recently, the amplification of nucleic acids from feces has been hindered by poor 
recovery due to the presence of nucleases.  DNA is much more stable than RNA and can 
typically be amplified from feces that have been snap-frozen in liquid nitrogen.  
However, due to the inherent instability of RNA and the abundance of prokaryotic 
nucleases in the feces, a preservative containing RNAse inhibitors is needed to isolate 
mRNA from feces.  When compared to several other methods of RNA preservation 
including liquid nitrogen, silica gel, Whatman FTA cards, and Paxgene, Yu et al. found 
RNAlater® to provide the optimal quantity and quality of RNA, as well as the lowest 
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level of genomic DNA contamination.  For our studies, two fecal pellets per mouse were 
collected in 200 µL of RNAlater® at each time point, yielding 600 to 800 ng/µL RNA 
per sample.  Assuming an average mass of 35 mg per fecal pellet, this results in an 
average yield of approximately 70 µg RNA per gram of feces.  An early description of a 
similar technique applied to human stool yielded from 5-30 µg RNA per gram of stool 
from CRC patients and approximately 5 µg RNA per gram from healthy controls
264
.  
Several points should be made regarding this difference.  An obvious caveat is the 
different methods of RNA extraction from feces.  While the present data represent RNA 
extracted using a commercially available kit from feces preserved in RNAlater®, the 
samples from human CRC patients and controls were snap frozen in liquid nitrogen, and 
RNA was extracted with acid phenol and chloroform.  A second consideration regarding 
differences in RNA recovery from mouse and human stool is the fate of senescent 
epithelial colonocytes.  In humans, effete colonocytes are primarily removed via mucosal 
phagocytosis, allowing subcellular components to be recycled
285
.  Alternatively, 
colonocytes in rodents are lost primarily via simple exfoliation into the lumen
285
.  Thus it 
would be expected that rodent feces would contain more RNA on a per weight basis and 
may be ideally suited to molecular techniques such as those described here.   
There is a strong likelihood that these techniques are applicable to other mouse models of 
colorectal cancer.  One would expect that post-inflammatory models of intestinal 
neoplasia would be particularly amenable to fecal cytokine or chemokine analysis.  
Several other strains of mice used as models of colitis are also prone to CRC, including 
IL-10
-/-
 mice
286
, IL-2
null × β2m
null
 mice
287
, and Gαi2
-/-
 mice
288
 among others.  In each 
model, while the development of colitis precedes CRC, suggesting that CRC is driven by 
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the inflammatory response, only 31 to 60% of mice in these models will progress to 
carcinoma
142
.  Thus, while the appropriate biomarkers and their kinetics would need to be 
established for each model (and possibly laboratory), the concept of predicting the 
presence or severity of disease through the use of fecal biomarkers of inflammation likely 
applies to more than just the Smad3
-/-
 mouse model.  Similarly, several fecal biomarkers, 
including RNA specific for cyclooxygenase-2 and matrix metalloproteinase-7, have 
garnered interest as screening tools for CRC in humans
279, 280
.  As microarray 
technologies become more commonplace, the use of fecal RNA analysis may allow for 
robust, non-invasive CRC screening in humans.  Smad3
-/-
 mice offer a useful tool for 
these types of studies and the refinement of the model described herein will enhance the 
development of both screening techniques and therapeutic modalities for CRC. 
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Gene  Sense (5’ – 3’)     Antisense (3’ – 5’)    
  Fragment size (bp)    Annealing temp. (°C)  
HPRT  GTAATGATCAGTCAACGGGGGAC  CCAGCAAGCTTGCAACCTTAACA 
  177      60 
18s rRNA GAACGTCTGCCCTATCAAC CCTCGAAAGAGTCCTGTATTG 
  201      58 
IL-1β  AGCCCATCCTCTGTGACTCATG GCTGATGTACCAGTTGGGGAAC 
  420      57 
MIP-1α  GCTCAACATCATGAAGGTCTCC TGCCGGTTTCTCTTAGTCAGG 
  222      57 
RANTES GAGTATTTCTACACCAGCAGC GGACTAGAGCAAGCAATGC 
  192      60 
MCP-2  ACTAAAGCTGAAGATCCCCCTTCG ACATCACCTGCTTGGTCTGGAAAA 
  100      57 
Table 1.  Sense and antisense primers, expected product sizes, and annealing 
temperatures used for real-time polymerase chain reaction amplification 
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CHAPTER 4 
BACKGROUND 
Murine Norovirus (MNV) is a recently discovered, non-enveloped virus with a linear, 
positive-sense, ssRNA genome, of the family Caliciviridae.  In humans, noroviruses are 
considered the primary cause of non-bacterial gastroenteritis, and are frequently food-
borne or waterborne pathogens
289-291
.  Both human and murine norovirus are relatively 
stable in the environment, however MNV was the first norovirus capable of cultivation, 
offering a useful tool for the study of human norovirus
292
.  Since this time, multiple 
diagnostic assays have been developed for the detection of MNV in mice including 
serologic and PCR-based assays
293
.   
A recent epidemiologic study detected antibodies against MNV1 in 22.1% of serum 
samples submitted from research facilities in North America making MNV the most 
common viral pathogen in research mouse populations
293
.  Despite the fact that MNV 
infection is typically subclinical, there is reasonable concern that MNV may be able to 
cause variation in mouse models of IBD such as DSS- or TNBS-induced colitis, for 
several reasons.  First, like human noroviruses, MNV resides in enteric tissues with the 
highest levels detected in the small intestines.  Second, the principal cellular targets of 
MNV within the gastrointestinal tract are macrophages and dendritic cells
294
.  Antigen-
presenting cells play important roles in most murine models of IBD, and viral infection 
may modulate their function in multiple ways.   
As intracellular microbes, viruses often induce an adaptive immune response 
characterized by IFN-γ-producing TH1 CD4
+
 T helper cells, the development of which is 
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dependent on IL-12 produced by dendritic cells and macrophages.  For example, in serum 
from humans experimentally infected with Snow Mountain Virus, a genogroup 2 
norovirus, or treated with Norwalk virus-like particles, significantly elevated levels of 
IFN-γ indicate an ongoing TH1 response
295, 296
.  Acute MNV infection may lead to a 
similar upregulation of IL-12 and IFN-γ, and thus enhance the inflammation seen in TH1-
dependent IBD models such as TNBS-induced colitis.  Additionally, MNV has been 
associated with an enhanced inflammatory response in one model of IBD with a 
concurrent increase in the number of splenic CD11c
+
 cells (dendritic cells). 
Alternatively, in models such as DSS-induced colitis, in which the inflammation is due to 
disruption of the epithelial barrier and increased permeability of epithelial tight junctions, 
antigen presenting cells (APCs) have been shown to have a protective effect. Mice 
experimentally depleted of macrophages and dendritic cells developed a more severe 
colitis following administration of DSS
297, 298
.  This is thought to be due to a loss of two 
APC functions: the regulation of neutrophil infiltration and activation, and the clearance 
of DSS from the gut
297
.  Thus, if infection with MNV adversely affects these APC 
functions, the inflammation induced by DSS may be exacerbated.  
Herein, we examined the effect of acute experimental MNV infection on both DSS-
induced, and TNBS-induced colitis, two commonly used mouse models of IBD 
characterized by acute inflammation.  Following the onset of administration of either 
compound, clinical signs and histopathological evidence of disease typically manifest 
within days
299
.  Using the routine outcomes measures of mortality, weight loss, and 
histological lesions, we were unable to detect an effect of MNV infection in either model.   
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MATERIALS AND METHODS 
Animals.  Five to six week old female SJL/J, BALB/cJ, and C57BL/6J mice (Jackson 
Laboratories, Bar Harbor, ME, USA) were group-housed in separate polycarbonate 
microisolator cages with filter tops, in a cubicle under negative pressure with a controlled 
environment of 21±2° C, 40-60% humidity, 15 air changes per hour, and 12:12h 
light:dark cycle.  Mice received pelleted mouse chow (Purina 5008 Formulab Diet; 
Purina Mills Inc., Richmond, IN, USA) and acidified water ad libitum.  Mice were 
allowed a minimum of 3 days for acclimation prior to any experimental manipulation.  
Mice were purchased from a colony that is historically free of common murine pathogens 
including MHV, MVM, MPV, Sendai, Mycoplasma pulmonis, TMEV, EDIM, PVM, 
Reo3, LCMV, Ectromelia, and Helicobacter spp.  Upon arrival, mice were confirmed to 
be negative for MNV by fecal PCR, performed at the Research Animal Diagnostic 
Laboratory (RADIL).  MNV infection was confirmed in the experimental group via PCR 
of feces collected at necropsy.  Housing and all procedures involving animals were 
performed according to a protocol approved by the University of Missouri Institutional 
Animal Care and Use Committee, and in compliance with the Animal Welfare Act and 
The Guide for The Care and Use of Laboratory Animals. 
Viral Propagation and Concentration.  MNV-4 was initially isolated from the 
mesenteric lymph nodes (MLN) of naturally-infected mice of various strains and stocks, 
positive for antibodies against MNV-4 by microbead fluorescent immunoassay as 
previously described 
293.  MLN were pooled in groups of 15 to 20 in 4 ml Dulbecco’s 
modified Eagle’s medium (Hyclone, Logan, UT) supplemented with 10% low-endotoxin 
fetal bovine serum (Cambrex, East Rutherford, NJ), 10 mM 4-(2-hydroxyethyl)-1-
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piperazineethanesulfonic acid, and 10 μg/ml ciprofloxacin (supplemented growth 
medium).  Pooled samples were processed in a blender (Stomacher 80 Lab Blender, 
Tekmar Company, Cincinnati, OH) and clarified by centrifugation for 10 min. at 
10,000×g.  RAW 264.7 cells were grown to 80% confluence in 25-cm
2
 cell culture flasks, 
and 1 ml clarified MLN homogenate was inoculated onto RAW cells and incubated for 1 
h at 37°C and 5% CO2, after which the inoculum was replaced with fresh supplemented 
growth medium and incubated for 1 h at 37°C and 5% CO2.  Cultures were monitored 
visually, and cells displaying cytopathic effect (CPE), suggestive of MNV infection, were 
pelleted at 2000×g for 10 min. at 4°C, and the clarified supernatants containing virus 
were frozen at -80°C.  Sham inoculations were similarly prepared RAW 264.7 cell 
cultures without added MNV. 
Plaque Assay.  The plaque assay was adapted from one previously described (Bac-N-
Blue transfection kit, Invitrogen, Carlsbad, CA). Briefly, RAW 264.7 cells were seeded 
onto 60-mm diameter tissue culture plates at a density of 5×10
6
 cells and allowed to 
adhere for 5 h at 37°C.  Tenfold serial dilutions of MNV-4 were made on ice using 
supplemented DMEM and inoculated in duplicate onto culture plates containing a 
confluent layer of RAW cells.  After inoculation for 1 h at 37°C, the inoculum was 
aspirated and replaced with a mixture of one part 2.5% SeaPlaque agarose and three parts 
supplemented DMEM, allowed to solidify, and incubated at 37°C for 24 to 48 h until 
plaques were visible.  For better visualization of the plaques, neutral red (0.01% final 
concentration) was added to 3 ml of the mixture containing 2.5% SeaPlaque agarose and 
supplemented DMEM, allowed to solidify, and incubated at 37°C for 6 to 8 h. 
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Infection with MNV-4.  Mice were inoculated via gastric gavage with approximately 0.2 
mL of clarified supernatant from MNV-4-infected RAW264.7 cell culture, containing 
approximately 1×10
7
 PFU of MNV-4.  Control mice were gavaged with an equivalent 
volume of clarified supernatant from an uninfected RAW264.7 cell culture.  Mice were 
group-housed according to MNV infection status prior to induction of colitis.  Both 
models of colitis were induced four days after infection. 
Induction of Experimental Colitis – DSS.  Dextran sulfate sodium (DSS: average 
molecular weight 36,000-50,000) was purchased from MP Biomedicals, LLC (Solon, 
OH, USA).  Experimental colitis was induced by giving drinking water containing 3.5% 
or 5.0% (wt/vol) DSS to C57BL/6J and BALB/cJ mice (n = 10), respectively for 5 days 
(changed daily), followed by normal drinking water for 5 days.  Mice were then 
sacrificed via an overdose of inhaled CO2 and the entire GI tract was collected for 
histopathological evaluation.   
Induction of Experimental Colitis – TNBS.  Trinitrobenzenesulfonic acid (TNBS) was 
purchased from Spectrum Chemical Mfg. Corp. (Gardena, CA, USA).  Mice were 
anesthetized via inhaled isoflurane, and either 1.0 or 2.5 mg TNBS in 150 μl of 50% 
ethanol was instilled per rectum using a 22g IV catheter (n = 40).  Mice were then 
suspended by the tail base for 20-30 seconds to minimize expulsion of the TNBS.  Mice 
were recovered from anesthesia in a cage lined with an absorbent material, as they often 
expelled a small portion of the TNBS upon recovery.  Four or ten days later (n = 20 per 
time point), mice were sacrificed via an overdose of inhaled CO2 and the entire GI tract 
was collected for histopathological evaluation.   
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Clinical Evaluation of Colitis.  Following induction of colitis, mice were weighed daily 
and evaluated for signs of illness, including hunched posture, rough haircoat, or lethargy.  
The presence of any of the above criteria was considered a clinical indication of disease.  
Mortality was also recorded as binary nominal data.  
Lesion Scores.  Gastrointestinal tracts were prepared as gut rolls and examined by two 
pathologists in a blinded fashion.  Briefly, for TNBS- and DSS-induced colitis, lesion 
severity was ranked based on the number and longitudinal extent of cecal and colonic 
erosions and ulcerations (0 to 3), the severity of inflammation (0 to 3), and in the case of 
DSS, evidence of hyperplasia (0 to 3), or in the case of TNBS, evidence of peritonitis (0 
to 3), Scores from the three categories were then added to yield a total histological lesion 
score ranging from zero to a maximum of nine.  Slides were then placed in order of their 
numeric lesion scores and compared, again in a blinded fashion, and ranked in order of 
severity.  Comparisons between MNV-infected and sham-inoculated mice was performed 
using ANOVA on ranks.   
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RESULTS 
DSS Colitis.  Previous studies have demonstrated differential susceptibility of various 
mouse strains to DSS-induced colitis.  While both C57BL/6J and BALB/cJ mice are 
considered susceptible, C57BL/6J mice require lower levels of DSS in the drinking water 
to avoid excessive mortality.  In addition, several differences have been demonstrated in 
the metabolic capacity of macrophages from these two mouse strains to respond to 
microbes
300, 301
.  Thus, considering the protective role of dendritic cells and macrophages 
in this model of colitis, we analyzed the effect of MNV in both strains.  Following 
administration of 3.5% or 5% DSS in the drinking water of C57BL/6J and BALB/cJ mice 
respectively, clinical signs were very subtle, and there was no mortality throughout the 
experiment in either strain of mice, independent of infection status.  Additionally, the 
mice were weighed daily and their weight normalized to their weights prior to induction 
of colitis. The weight of the mice in the MNV-infected and sham-inoculated groups did 
not differ significantly (figure 4.1) in either mouse strain.   
Following administration of DSS for consecutive five days followed by five days without 
DSS, mice were euthanized and their entire GIT from jejunem to rectum was collected 
for histological analysis, which revealed a loss of crypt architecture, mild to moderate 
inflammation, (figure 4.2) in the majority of mice, and occasional ulceration in a few.  
Lesions were confined to the colon and, to a lesser degree, the cecum.  A total lesion 
score was generated for each mouse based on the degree of ulceration, inflammation, and 
hyperplasia.  While there was a trend toward higher lesion scores in the C57BL/6J mice 
when compared to the BALB/cJ, there was no significant difference in the lesion scores 
of MNV-infected and sham-inoculated mice, in either strain (figure 4.3).   
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TNBS Colitis.  As with DSS-induced colitis, one group of mice was orally gavaged with 
MNV-4 four days prior to induction of colitis, while the control group was sham 
inoculated with an equivalent volume of RAW 264.7 culture supernatant.  A dosage of 
2.5 mg of TNBS per mouse was used for all experiments as preliminary studies showed 
that this produced more consistent inflammation in SJL/J mice than did 1.0 mg TNBS.  
Following administration of TNBS, mice were weighed daily and their weight was 
normalized to their weight at day 0.  As in DSS-induced colitis, there was no significant 
difference in weight loss between the two groups (figure 4.4).  Clinical signs and 
mortality were sporadic in both groups however and no differences in survival were 
detected between MNV-infected and sham-inoculated mice (figure 4.5).  Considering the 
acute nature of TNBS-induced colitis, samples were collected at both day 4 and day 10, 
for histopathological analysis and lesion scoring.   Lesions included focal and multifocal 
areas of ulceration and inflammation characterized by infiltrates of mononuclear cells and 
neutrophils (figures 4.6A and B).  Several mice had areas of transmural inflammation 
resulting in inflammatory infiltrates reaching the peritoneal cavity (figures 4.6C and D).  
Lesion scores were higher at the 4 day time point than at day 10 in both groups but again, 
there was no difference detected between the two groups at either time point (figure 4.7). 
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DISCUSSION 
Following the recent discovery of MNV, several groups began to question its ability to 
induce inflammation in various mouse strains, or affect the outcome of mouse models of 
disease.  Despite the ability of MNV to rapidly disseminate to multiple tissues in 
immunocompetent mice
302
, it appears to be subclinical in all immunocompetent strains 
and stocks examined to date, including 129S6/SvEvTac, C57BL/6, Tac:SW, Hsd:ICR 
mice
293, 303, 304
.  Similarly, histological lesions are not seen in naturally infected 
immunocompetent mice and even acute experimentally-induced lesions are extremely 
mild and transient
302
.  Highlighting the importance of the innate immune system in 
response to MNV infection, Rag
-/-
 mice lacking functional T and B cell receptors do not 
develop clinical signs or histological lesions while mice deficient for STAT1 or IFNαβγR 
rapidly succumb to MNV infection due to hepatic and pulmonary inflammation
302, 305
.  
Thus it appears that an intact IFN signaling pathway is essential for prevention of MNV-
induced lesions.  While MNV does not induce de novo lesions in immunocompetent 
mice, it is possible however that MNV may alter experimentally induced inflammation.  
Considering the anatomical and cellular tropisms of MNV, we studied two commonly 
used mouse models of IBD, DSS- and TNBS-induced colitis.     
In humans, several studies have attempted to link persistent or prior viral infection, as 
well as vaccination against, or in utero exposure to, a viral pathogen with subsequent 
IBD
59, 60, 66, 306
.  While these reports have uniformly failed to provide a causal link 
between viral infection and subsequent IBD
307
, some have demonstrated an increased 
relative risk of developing IBD later in life following exposure to certain viruses
308, 309
.  
Regarding murine models of IBD, it is unknown whether typically subclinical enteric 
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viral infection may alter the disease phenotype.  MNV is a highly prevalent, enteric virus 
of mice that resides in APCs making it a potential confounding factor in IBD research 
using mouse models.   
We chose to examine the effect of MNV on the DSS and TNBS colitis models based on 
their popularity in the IBD research community, as well as their complementary disease 
mechanisms
299
.  While TNBS is generally accepted to be mediated by a combined 
TH1/TH17 adaptive immune response, DSS colitis is driven by an innate response 
following disruption of the epithelial barrier and crypt loss.  Additionally, we chose to 
include both C57BL/6 and BALB/c mouse strains in our DSS studies based on reported 
differences in the metabolic capacity of macrophages.   
Our data support the notion that MNV is unlikely to significantly alter the disease 
phenotype in these models of IBD, at least with regard to the commonly measured 
outcomes such as mortality and histologic evidence of inflammation.  In our studies, 
there was no difference in weight loss, clinical signs, mortality, or severity of histological 
lesions in either DSS- or TNBS-induced colitis.  It should be remembered however that 
this does not preclude MNV from affecting other models of IBD.  Chase et al. 
demonstrated that infection with MNV affects weight loss and histological disease 
severity in Helicobacter bilis-infected MDR1a
-/-
 mice
310
.  Thus, as different models of 
IBD have different mechanisms and can sometimes be performed on more than one strain 
of mouse, the relevance of MNV infection in experimental subjects must be considered 
on an individual basis.  In addition, we measured clinical signs including weight and 
histological lesions.  While we were unable to detect differences in these endpoints, that 
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is clearly not to say that infection with MNV does not cause perturbations in cytokine 
expression and other parameters. 
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CHAPTER 5 
Comparative medicine is founded on the concept that through the use of appropriate 
animal models of disease, knowledge can be gained regarding the human condition, with 
the ultimate goal of translating that knowledge into useful therapeutic and diagnostic 
modalities.  In the studies described herein, Helicobacter-induced mouse models of 
inflammatory bowel disease and colitis-associated colorectal cancer were chosen due to 
their phenotypic similarities to the human diseases, but also due to the fact that the 
inflammation in these models is putatively driven by not just H. hepaticus and H. bilis, 
but also the commensal intestinal microbiota, as is believed to occur in IBD.  The studies 
described in chapters 2 and 3 generated several exciting findings, each with the potential 
to be directly translated to human gastroenterology and oncology.   
In chapter 2, we generated several pieces of evidence supporting the hypothesis that 
CD8α+ dendritic cells DC) are involved in the initiation of an inflammatory cascade 
which takes months to manifest.  Of note, we determined that while multiple DC subsets 
are present in significantly greater numbers in naïve mice which considered susceptible to 
H. hepaticus-induced cecal inflammation, the CD8α+CD11b- and CD8α-CD11b- (double 
negative, DN) subsets are preferentially recruited to the cecum following inoculation with 
H. hepaticus.  Additionally, while cells from the susceptible mouse strain produce greater 
amounts of IL-12/23p40 than cells from a resistant mouse strain when naïve mice are 
used, cells from the susceptible mouse strain acutely infected with H. hepaticus produce 
significantly greater amounts of TNF-α, CXCL10 (IP-10), and CCL5 (RANTES).  While 
previous studies had demonstrated increased transcription of several of these factors in 
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susceptible mice, confirmation that these inflammatory mediators are expressed at a 
significantly greater level at the protein level is an essential step in selecting molecules as 
therapeutic targets.  Current biologic therapies targeting TNF-α are currently available for 
IBD patients, lending additional support for the use of H. hepaticus-infected A/J mice as 
a model of IBD.  However, due to the heterogeneous nature of IBD, not all patients 
respond to anti-TNF-α therapy, suggesting that other molecules, both immunologic and 
otherwise, are needed.  Chemokines offer one possibility for therapeutic targets.  Perhaps 
by blocking the homing of inflammatory cells back to the GIT, disease can be abrogated. 
Of particular interest is the data supporting a role for CD8α+ DC in disease initiation.  
Future studies will confirm the physiological role of this subset of DC in the pathogenesis 
of H. hepaticus-induced inflammation.  We plan to inoculate wild type and Batf3-
deficient A/J mice with H. hepaticus, and then collect intestinal tissue from these mice at 
acute and chronic time points, to determine if the absence of CD8α+ DC is associated 
with a decrease or complete lack of inflammation.  If the in vivo data confirm our 
hypothesis, this will provide some of the most compelling evidence of a role for a 
specific subset of DC in the pathogenesis of IBD.  While this discovery would advance 
our overall understanding of IBD, it would be particularly exciting in light of recent 
developments in the field of gene therapy.  Novel chemical conjugates have increased the 
cell specificity of gene delivery
311
, diminishing potential side effects.  The ability to 
selectively deliver gene therapy to a specific subset of DC would therefore enhance the 
safety of these treatments.  Of note, gene therapy augmenting PPARγ was recently shown 
to ameliorate inflammation in DSS-induced colitis
312
. 
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We have also begun co-infection studies examining the effect of segmented filamentous 
bacteria (SFB) on the H. hepaticus-infected A/J model.  SFB has a role in the 
development of both regulatory T cells
313
 and TH17 T cells
314
.  Accordingly, these 
bacteria are thought to play a large role in shaping the gut immune response as well as the 
composition of the microbiota.  These studies will also incorporate analyses of the 
microbiota using multiple techniques including automated ribosomal intergenic spacer 
analysis (ARISA) and deep sequencing of the 16s rRNA gene. 
The data from chapter 3 portend novel methods of screening IBD patients for dysplasia, 
an early stage of colitis-associated colorectal cancer (CAC).  In H. bilis-infected Smad3
-/-
 
mice, we were able to reliably detect early stages of disease using fecal mRNA-based 
biomarkers.  Additionally, the expression of certain inflammatory mediators early after 
inoculation with H. bilis correlated with disease severity several weeks later, thus serving 
as a prognostic indicator.  These findings are extremely exciting considering the 
weaknesses of current screening techniques for CAC in humans.  Inexpensive and 
noninvasive techniques such as fecal occult blood tests suffer from very poor specificity.  
Thus many patients will undergo unnecessary confirmatory colonoscopy.  Colonoscopy 
in itself offers relatively decent accuracy in tumors of the distal colon, however masses in 
the proximal colon are often inaccessible.  Also of concern is the unpleasant and invasive 
nature of colonoscopy, attributes cited by IBD patients as reasons for noncompliance 
with the screening recommendations of the American Gastroenterological Association.  
Other noninvasive techniques such as virtual colonoscopy are expensive and require 
considerable expertise in their interpretation.  Molecular techniques have the potential to 
provide inexpensive, noninvasive diagnoses capable of being performed with minimal 
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special equipment.  Additionally, methods using feces as the diagnostic sample could be 
performed with submitted samples, enhancing compliance by patients for whom travel to 
a clinic is problematic or impossible such as senior citizens, individuals living in rural 
communities, and deployed soldiers.  There are currently molecular assays available for 
Lynch syndrome (hereditary nonpolyposis colorectal cancer) and familial adenomatous 
polyposis, the two recognized forms of hereditary colorectal cancer (CRC) which account 
for approximately 3 and 1% of CRC respectively.  These assays utilize standard PCR 
methodology to identify polymorphic alleles of the genes associated with disease.  While 
there are several genetic polymorphisms that have been associated with IBD, none have 
been identified in IBD patients as being responsible for an increased risk of developing 
CAC.  There is evidence to support the notion that increased duration, severity, and 
longitudinal extent of inflammation in the colon increases the risk of CAC.  Thus, fecal 
expression-based biomarkers using reverse-transcription PCR methodology may offer an 
effective means of monitoring the expression of various mediators noninvasively and 
affordably.  Additionally, if specific biomarkers could be correlated with the very early 
stages of CAC development, i.e. dysplasia, disease could be treated more effectively and 
affordably. 
To this end, we have established research team consisting of a biostatistician with 
experience in the analysis of large and complex biological data sets, and a consortium of 
gastroenterologists including clinicians from the University of Missouri, Washington 
University in St. Louis, the John Cochran VA Medical Center in St. Louis, and a local 
group of seven gastroenterologists in Columbia, all of whom perform routine annual 
colonoscopic screening of IBD patients for dysplasia.  We’re actively pursuing funding 
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opportunities to translate the technique described in chapter 3 to an at-risk human 
population, namely IBD patients.  Briefly, our experimental design is to obtain 
permission to have access to the results of colonoscopies, and then obtain a fecal sample 
from those patients in whom areas of dysplasia are identified (and an equivalent number 
of non-dysplastic IBD patients).  RNA will be isolated from feces and the entire 
transcriptome screened using RNA-Seq technology
315
 to identify genes that are 
differentially transcribed between the two groups.  Promising candidate genes will then 
be verified using individual RT-PCR reactions.  Our goal is to identify a distinct 
expression-based signature correlating with dysplasia for use clinically as a screening 
method tailored to IBD patients.  This technique has far-reaching implications in the 
diagnosis of other enteropathies and the studies described in chapter 3 provide proof-of-
concept. 
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